|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q37830471
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241120235913.0 |
|
008
|
|
|
241120nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q37830471
|
|
024
|
|
|
‡a
0000-0002-9728-9992
‡2
orcid
|
|
024
|
|
|
‡a
0000-0002-1195-039X
‡2
orcid
|
|
024
|
|
|
‡a
55629533100
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q37830471
|
|
100
|
0 |
|
‡a
David Price
‡9
ast
‡9
it
‡9
sl
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
ডেভিড প্রাইস
‡9
bn
|
|
400
|
0 |
|
‡a
Ντέιβιντ Πράις
‡9
el
|
|
400
|
0 |
|
‡a
David Price
‡c
Professor of Primary Care Respiratory Medicine
‡9
en
|
|
400
|
0 |
|
‡a
David Price
‡c
investigador
‡9
es
|
|
400
|
0 |
|
‡a
David Price
‡c
chercheur
‡9
fr
|
|
400
|
0 |
|
‡a
David Price
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's 2016 Respiratory Effectiveness Group Annual Summit Report-impact & influence of real-world respiratory evidence.
|
|
670
|
|
|
‡a
Author's A BOLD statement on how to case-find moderate/severe COPD.
|
|
670
|
|
|
‡a
Author's A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
|
|
670
|
|
|
‡a
Author's A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD
|
|
670
|
|
|
‡a
Author's A multinational observational study identifying primary care patients at risk of overestimation of asthma control
|
|
670
|
|
|
‡a
Author's A new efficacy parameter
|
|
670
|
|
|
‡a
Author's A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*.
|
|
670
|
|
|
‡a
Author's A new therapy
|
|
670
|
|
|
‡a
Author's A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity.
|
|
670
|
|
|
‡a
Author's A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex.
|
|
670
|
|
|
‡a
Author's A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion.
|
|
670
|
|
|
‡a
Author's A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis
|
|
670
|
|
|
‡a
Author's A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis.
|
|
670
|
|
|
‡a
Author's A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis
|
|
670
|
|
|
‡a
Author's A Patient-Centered Description of Severe Asthma: Patient Understanding Leading to Assessment for a Severe Asthma Referral (PULSAR)
|
|
670
|
|
|
‡a
Author's A pilot study to assess the feasibility and acceptability of undertaking acute asthma professional development in three different UK primary care settings
|
|
670
|
|
|
‡a
Author's A practical tool for primary care antimicrobial stewardship in children
|
|
670
|
|
|
‡a
Author's A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines
|
|
670
|
|
|
‡a
Author's A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study).
|
|
670
|
|
|
‡a
Author's A pragmatic, three-arm randomised controlled trial of spiritual healing for asthma in primary care
|
|
670
|
|
|
‡a
Author's A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults
|
|
670
|
|
|
‡a
Author's A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma
|
|
670
|
|
|
‡a
Author's A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease
|
|
670
|
|
|
‡a
Author's A real-life comparative effectiveness study into the addition of antibiotics to the management of asthma exacerbations in primary care
|
|
670
|
|
|
‡a
Author's A survey on the management of acute rhinosinusitis among Asian physicians.
|
|
670
|
|
|
‡a
Author's A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.
|
|
670
|
|
|
‡a
Author's A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice
|
|
670
|
|
|
‡a
Author's AB012. Current burden of uncontrolled asthma in the general population: the OPCRD asthma state of the Union study.
|
|
670
|
|
|
‡a
Author's AB013. Inappropriate asthma therapy: a tale of two countries.
|
|
670
|
|
|
‡a
Author's AB027. Long-acting beta-agonist in combination or separate inhaler as step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
|
|
670
|
|
|
‡a
Author's AB032. Opportunities for real-life respiratory research in Korea: the HIRA database and beyond.
|
|
670
|
|
|
‡a
Author's AB034. Comparative effectiveness of prescribing similarversusdissimilar inhalers for COPD therapy.
|
|
670
|
|
|
‡a
Author's AB037. Drug-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases.
|
|
670
|
|
|
‡a
Author's AB038. Pragmatic trial comparing continuing Seretide® MDI with changing to Flutiform® in asthma.
|
|
670
|
|
|
‡a
Author's AB039. Pragmatic trial stepping down Flutiform® in patients maintained on high dose ICS.
|
|
670
|
|
|
‡a
Author's AB040. Determinants of increase FeNO in individuals with suspected asthma.
|
|
670
|
|
|
‡a
Author's AB041. Effectiveness and cost impact evaluation of fluticasone propionate/formoterol compared to fluticasone propionate/salmeterol.
|
|
670
|
|
|
‡a
Author's AB042. Allergy Working Group Update: the burden and management of rhinitis and rhinosinusitis in UK primary care.
|
|
670
|
|
|
‡a
Author's ABC of chronic obstructive pulmonary disease. Primary care and palliative care
|
|
670
|
|
|
‡a
Author's ABS004: The concept, prevalence and consequences of low tolerance to ICS in asthma
|
|
670
|
|
|
‡a
Author's ABS008: Asthma management and the PCP: Findings of the global asthma physician and patient (GAPP) survey
|
|
670
|
|
|
‡a
Author's ABS29: The SMART plan: development of a symptom-based asthma action plan for single inhaler therapy
|
|
670
|
|
|
‡a
Author's ABS41: Montelukast as first-line preventative treatment for asthma in children age 2-5 yrs: A retrospective study
|
|
670
|
|
|
‡a
Author's ABS74: Large variations in asthma control between UK general practices participating in the asthma control, concordance and tolerance (ACCT) Initiative
|
|
670
|
|
|
‡a
Author's Accessibility, acceptability, and effectiveness in primary care of routine telephone review of asthma: pragmatic, randomised controlled trial
|
|
670
|
|
|
‡a
Author's Achieving asthma control in practice: understanding the reasons for poor control
|
|
670
|
|
|
‡a
Author's Achieving optimal asthma control: Can this be informed by recent studies of professional-patient communication?
|
|
670
|
|
|
‡a
Author's Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
|
|
670
|
|
|
‡a
Author's Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study
|
|
670
|
|
|
‡a
Author's Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease
|
|
670
|
|
|
‡a
Author's Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study
|
|
670
|
|
|
‡a
Author's Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
|
|
670
|
|
|
‡a
Author's Advancing the Patient EXperience (APEX) in COPD Registry: Study Design and Strengths
|
|
670
|
|
|
‡a
Author's Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study
|
|
670
|
|
|
‡a
Author's Age and Sex Associations with Systemic Corticosteroid-Induced Morbidity in Asthma
|
|
670
|
|
|
‡a
Author's Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
|
|
670
|
|
|
‡a
Author's Allergic Rhinitis and its Impact on Asthma
|
|
670
|
|
|
‡a
Author's Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs
|
|
670
|
|
|
‡a
Author's Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision
|
|
670
|
|
|
‡a
Author's An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study
|
|
670
|
|
|
‡a
Author's An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom
|
|
670
|
|
|
‡a
Author's An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma
|
|
670
|
|
|
‡a
Author's An exploratory, pragmatic, cluster randomised trial of practice nurse training in the use of asthma action plans.
|
|
670
|
|
|
‡a
Author's An innovative corticosteroid/long-acting β2-agonist breath-triggered inhaler: facilitating lung delivery of fluticasone propionate/formoterol fumarate for the treatment of asthma
|
|
670
|
|
|
‡a
Author's Antibiotic prescribing and outcomes of lower respiratory tract infection in UK primary care.
|
|
670
|
|
|
‡a
Author's Applying UK real-world primary care data to predict asthma attacks in 3776 well-characterised children: a retrospective cohort study
|
|
670
|
|
|
‡a
Author's Are pharmacological randomised controlled clinical trials relevant to real-life asthma populations? A protocol for an UNLOCK study from the IPCRG.
|
|
670
|
|
|
‡a
Author's ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice
|
|
670
|
|
|
‡a
Author's ARIA update: I--Systematic review of complementary and alternative medicine for rhinitis and asthma
|
|
670
|
|
|
‡a
Author's Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD.
|
|
670
|
|
|
‡a
Author's Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study
|
|
670
|
|
|
‡a
Author's Association between COPD exacerbations and lung function decline during maintenance therapy
|
|
670
|
|
|
‡a
Author's Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
|
|
670
|
|
|
‡a
Author's Asthma Across Age: Insights From Primary Care
|
|
670
|
|
|
‡a
Author's Asthma and allergic rhinitis: Linked in treatment and outcomes
|
|
670
|
|
|
‡a
Author's Asthma at-risk registers--can be effective if carefully constructed and correctly implemented
|
|
670
|
|
|
‡a
Author's Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey
|
|
670
|
|
|
‡a
Author's Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study
|
|
670
|
|
|
‡a
Author's Asthma in Asia: Physician perspectives on control, inhaler use and patient communications.
|
|
670
|
|
|
‡a
Author's Asthma out of control? A structured review of recent patient surveys
|
|
670
|
|
|
‡a
Author's Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone
|
|
670
|
|
|
‡a
Author's Asthma referrals: a key component of asthma management that needs to be addressed
|
|
670
|
|
|
‡a
Author's Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis
|
|
670
|
|
|
‡a
Author's Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids
|
|
670
|
|
|
‡a
Author's Asthma-specific health-related quality of life of people in Great Britain: A national survey
|
|
670
|
|
|
‡a
Author's Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis
|
|
670
|
|
|
‡a
Author's Befriending carers of people with dementia: a cost utility analysis
|
|
670
|
|
|
‡a
Author's Befriending carers of people with dementia: randomised controlled trial
|
|
670
|
|
|
‡a
Author's Blood eosinophil count and exacerbation risk in patients with COPD.
|
|
670
|
|
|
‡a
Author's Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
|
|
670
|
|
|
‡a
Author's Breaking new ground: challenging existing asthma guidelines
|
|
670
|
|
|
‡a
Author's Breathing exercises for asthma: a randomised controlled trial.
|
|
670
|
|
|
‡a
Author's Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
|
|
670
|
|
|
‡a
Author's Can a GP be a generalist and a specialist? Stakeholders views on a respiratory General Practitioner with a special interest service in the UK.
|
|
670
|
|
|
‡a
Author's Can asthma control be improved by understanding the patient's perspective?
|
|
670
|
|
|
‡a
Author's Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study
|
|
670
|
|
|
‡a
Author's Challenges of COPD diagnosis
|
|
670
|
|
|
‡a
Author's Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.
|
|
670
|
|
|
‡a
Author's Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study
|
|
670
|
|
|
‡a
Author's Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observational
|
|
670
|
|
|
‡a
Author's Characteristics and first treatment dose of Dutch patients
|
|
670
|
|
|
‡a
Author's Characteristics and first treatment dose of Dutch patients (12-60 years old) receiving prescriptions for asthma and initiating inhaled corticosteroids (ICS) therapy as either extra-fine (EF) ciclesonide or standard-particle (SP)-ICS.
|
|
670
|
|
|
‡a
Author's Characteristics of patients in platform C19, a COVID-19 research database combining primary care electronic health record and patient reported information
|
|
670
|
|
|
‡a
Author's Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting.
|
|
670
|
|
|
‡a
Author's Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study
|
|
670
|
|
|
‡a
Author's Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry
|
|
670
|
|
|
‡a
Author's Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs
|
|
670
|
|
|
‡a
Author's Chronic cough. Article is not consistent with WHO initiative on rhinitis and asthma
|
|
670
|
|
|
‡a
Author's Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial
|
|
670
|
|
|
‡a
Author's Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients
|
|
670
|
|
|
‡a
Author's Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database
|
|
670
|
|
|
‡a
Author's Clinical implications of the Royal College of Physicians three questions in routine asthma care: a real-life validation study.
|
|
670
|
|
|
‡a
Author's Clinical management. Getting up to scratch
|
|
670
|
|
|
‡a
Author's Clinical trials and tribulations: the MASCOT study
|
|
670
|
|
|
‡a
Author's Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dip
|
|
670
|
|
|
‡a
Author's Clinically relevant effect of a new intranasal therapy
|
|
670
|
|
|
‡a
Author's Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis
|
|
670
|
|
|
‡a
Author's Co-morbid disease in COPD--more than a coincidence.
|
|
670
|
|
|
‡a
Author's Community-acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general practice.
|
|
670
|
|
|
‡a
Author's Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease
|
|
670
|
|
|
‡a
Author's Comorbidity among the morbidly obese: a comparative study of 2002 U.S. hospital patient discharges.
|
|
670
|
|
|
‡a
Author's Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry
|
|
670
|
|
|
‡a
Author's Comparative Effectiveness of Step-up Therapies in Children with Asthma Prescribed Inhaled Corticosteroids: A Historical Cohort Study
|
|
670
|
|
|
‡a
Author's Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
|
|
670
|
|
|
‡a
Author's Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β2-Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary Care
|
|
670
|
|
|
‡a
Author's Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD
|
|
670
|
|
|
‡a
Author's Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma
|
|
670
|
|
|
‡a
Author's Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study
|
|
670
|
|
|
‡a
Author's Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis
|
|
670
|
|
|
‡a
Author's Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial
|
|
670
|
|
|
‡a
Author's Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study.
|
|
670
|
|
|
‡a
Author's Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study
|
|
670
|
|
|
‡a
Author's Complementing the randomized controlled trial evidence base. Evolution not revolution.
|
|
670
|
|
|
‡a
Author's Concept review of dry powder inhalers: correct interpretation of published data
|
|
670
|
|
|
‡a
Author's Concerns of patients with allergic rhinitis: the Allergic Rhinitis Care Programme in South Africa.
|
|
670
|
|
|
‡a
Author's COPD case finding: effective, but also cost-effective?
|
|
670
|
|
|
‡a
Author's COPD phenotypes and machine learning cluster analysis: A systematic review and future research agenda
|
|
670
|
|
|
‡a
Author's COPD Population in US Primary Care: Data From the Optimum Patient Care DARTNet Research Database and the Advancing the Patient Experience in COPD Registry
|
|
670
|
|
|
‡a
Author's COPD screening efforts in primary care: what is the yield?
|
|
670
|
|
|
‡a
Author's Corrigendum to “Progressive breathlessness in COPD — The role of hyperinflation and its pharmacological management” [Prim Care Resp J 2005; 14 (6): 285-293]
|
|
670
|
|
|
‡a
Author's Corrigendum to ‘The use of roflumilast in COPD: a primary care perspective’ ( 2010;19(4) (Suppl 2):342–351)
|
|
670
|
|
|
‡a
Author's Cost comparison of asthma treatments in 12-week study: caution about matching and short observational follow-up
|
|
670
|
|
|
‡a
Author's Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study.
|
|
670
|
|
|
‡a
Author's Cost effectiveness of asthma management strategies
|
|
670
|
|
|
‡a
Author's Cost-Effectiveness of Asthma Step-Up Therapy as an Increased Dose of Extrafine-Particle Inhaled Corticosteroid or Add-On Long-Acting Beta2-Agonist
|
|
670
|
|
|
‡a
Author's Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy
|
|
670
|
|
|
‡a
Author's Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden
|
|
670
|
|
|
‡a
Author's Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study
|
|
670
|
|
|
‡a
Author's Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy
|
|
670
|
|
|
‡a
Author's Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma
|
|
670
|
|
|
‡a
Author's Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma
|
|
670
|
|
|
‡a
Author's Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial
|
|
670
|
|
|
‡a
Author's Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting
|
|
670
|
|
|
‡a
Author's Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist
|
|
670
|
|
|
‡a
Author's Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Ob
|
|
670
|
|
|
‡a
Author's Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
|
|
670
|
|
|
‡a
Author's Could interchangeable use of dry powder inhalers affect patients?
|
|
670
|
|
|
‡a
Author's Current control and future risk in asthma management
|
|
670
|
|
|
‡a
Author's Current controversies and challenges in allergic rhinitis management
|
|
670
|
|
|
‡a
Author's Current evidence and future research needs for FeNO measurement in respiratory diseases
|
|
670
|
|
|
‡a
Author's Database studies in asthma pharmacoeconomics: uses, limitations and quality markers
|
|
670
|
|
|
‡a
Author's Defining severe obstructive lung disease in the biologic era: an endotype-based approach
|
|
670
|
|
|
‡a
Author's Definitions of severe and difficult asthma by a group of UK general practitioners
|
|
670
|
|
|
‡a
Author's Delivering a drug study in primary care: trial management challenges and solutions.
|
|
670
|
|
|
‡a
Author's Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index.
|
|
670
|
|
|
‡a
Author's Detecting mild COPD is not a waste of resources
|
|
670
|
|
|
‡a
Author's Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study
|
|
670
|
|
|
‡a
Author's Development and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paper
|
|
670
|
|
|
‡a
Author's Development and Validation of an Attitudinal-Profiling Tool for Patients With Asthma
|
|
670
|
|
|
‡a
Author's Development of a primary-care tool to assess treatment success in COPD: consensus report from a closed meeting of respiratory and primary-care specialists
|
|
670
|
|
|
‡a
Author's Development of the Advancing the Patient Experience in COPD Registry: A Modified Delphi Study
|
|
670
|
|
|
‡a
Author's Development of the International Severe Asthma Registry
|
|
670
|
|
|
‡a
Author's Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study
|
|
670
|
|
|
‡a
Author's Device type and real-world effectiveness of asthma combination therapy: An observational study
|
|
670
|
|
|
‡a
Author's Differential effects of inhaled corticosteroids in smokers/ex-smokers and nonsmokers with asthma
|
|
670
|
|
|
‡a
Author's Distribution, Temporal Stability and Appropriateness of Therapy of Patients With COPD in the UK in Relation to GOLD 2019
|
|
670
|
|
|
‡a
Author's Do people self-reporting information about chronic respiratory disease have corroborative evidence in their general practice medical records? A study of intermethod reliability.
|
|
670
|
|
|
‡a
Author's Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation
|
|
670
|
|
|
‡a
Author's Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study.
|
|
670
|
|
|
‡a
Author's Driving asthma care in Europe: the Brussels Declaration
|
|
670
|
|
|
‡a
Author's Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review
|
|
670
|
|
|
‡a
Author's Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease
|
|
670
|
|
|
‡a
Author's Earlier diagnosis and earlier treatment of COPD in primary care.
|
|
670
|
|
|
‡a
Author's Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults
|
|
670
|
|
|
‡a
Author's Effect of montelukast for treatment of asthma in cigarette smokers
|
|
670
|
|
|
‡a
Author's Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial
|
|
670
|
|
|
‡a
Author's Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study
|
|
670
|
|
|
‡a
Author's Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial
|
|
670
|
|
|
‡a
Author's Effective deployment of technology-supported management of chronic respiratory conditions: a call for stakeholder engagement
|
|
670
|
|
|
‡a
Author's Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu.
|
|
670
|
|
|
‡a
Author's Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD.
|
|
670
|
|
|
‡a
Author's Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands
|
|
670
|
|
|
‡a
Author's Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study
|
|
670
|
|
|
‡a
Author's Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care
|
|
670
|
|
|
‡a
Author's Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study.
|
|
670
|
|
|
‡a
Author's Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: a pooled analysis.
|
|
670
|
|
|
‡a
Author's Efficacy versus effectiveness trials: informing guidelines for asthma management
|
|
670
|
|
|
‡a
Author's Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSS
|
|
670
|
|
|
‡a
Author's Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
|
|
670
|
|
|
‡a
Author's EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists
|
|
670
|
|
|
‡a
Author's EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007 - a summary.
|
|
670
|
|
|
‡a
Author's Erratum: Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study
|
|
670
|
|
|
‡a
Author's Erratum: Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database [Corrigendum]
|
|
670
|
|
|
‡a
Author's Erratum: Predicting frequent COPD exacerbations using primary care data [Corrigendum]
|
|
670
|
|
|
‡a
Author's Erratum to: Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands
|
|
670
|
|
|
‡a
Author's European Position Paper on Rhinosinusitis and Nasal Polyps 2012.
|
|
670
|
|
|
‡a
Author's European Symposium on Precision Medicine in Allergy and Airways Diseases: Report of the European Union Parliament Symposium (October 14, 2015).
|
|
670
|
|
|
‡a
Author's Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
|
|
670
|
|
|
‡a
Author's Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD
|
|
670
|
|
|
‡a
Author's Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time
|
|
670
|
|
|
‡a
Author's Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study.
|
|
670
|
|
|
‡a
Author's Exacerbations of chronic obstructive pulmonary disease--a patients' perspective.
|
|
670
|
|
|
‡a
Author's Exogenous sex steroid hormones and asthma in females: protocol for a population-based retrospective cohort study using a UK primary care database.
|
|
670
|
|
|
‡a
Author's Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma: A Delphi Study
|
|
670
|
|
|
‡a
Author's Exploring the role of quantitative feedback in inhaler technique education: a cluster-randomised, two-arm, parallel-group, repeated-measures study
|
|
670
|
|
|
‡a
Author's Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study
|
|
670
|
|
|
‡a
Author's Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies
|
|
670
|
|
|
‡a
Author's Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey.
|
|
670
|
|
|
‡a
Author's Feasibility and ethics
|
|
670
|
|
|
‡a
Author's FGF8 morphogen gradients are differentially regulated by heparan sulphotransferases Hs2st and Hs6st1 in the developing brain
|
|
670
|
|
|
‡a
Author's First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis
|
|
670
|
|
|
‡a
Author's Flawed Comparative Groups Lead to Flawed Conclusions: Response
|
|
670
|
|
|
‡a
Author's Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care
|
|
670
|
|
|
‡a
Author's Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
|
|
670
|
|
|
‡a
Author's FourFold Asthma Study
|
|
670
|
|
|
‡a
Author's FourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations.
|
|
670
|
|
|
‡a
Author's Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial
|
|
670
|
|
|
‡a
Author's From awareness to involvement? A qualitative study of respiratory patients' awareness of health service change.
|
|
670
|
|
|
‡a
Author's From support to boundary: a qualitative study of the border between self-care and professional care
|
|
670
|
|
|
‡a
Author's Gastroesophageal reflux disease and asthma: a longitudinal study in UK general practice
|
|
670
|
|
|
‡a
Author's General practitioners' understanding of severe and difficult asthma: A qualitative study
|
|
670
|
|
|
‡a
Author's General practitioners with a special clinical interest: a model for improving respiratory disease management
|
|
670
|
|
|
‡a
Author's General practitioners with a special interest in respiratory medicine: national survey of UK primary care organisations
|
|
670
|
|
|
‡a
Author's GOLD COPD categories are not fit for purpose in primary care.
|
|
670
|
|
|
‡a
Author's Guided self management plans for asthma. Advice should be simple and patient focused.
|
|
670
|
|
|
‡a
Author's Guidelines for allergic rhinitis need to be used in primary care
|
|
670
|
|
|
‡a
Author's Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal
|
|
670
|
|
|
‡a
Author's Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population
|
|
670
|
|
|
‡a
Author's Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma
|
|
670
|
|
|
‡a
Author's High-dose inhaled corticosteroid use in childhood asthma: an observational study of GP prescribing
|
|
670
|
|
|
‡a
Author's High-dose inhaled corticosteroids and add-on therapy use in adults with asthma in the UK in 2003: an observational study
|
|
670
|
|
|
‡a
Author's High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: an observational study
|
|
670
|
|
|
‡a
Author's Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease
|
|
670
|
|
|
‡a
Author's Historical database cohort study addressing the clinical patterns prior to idiopathic pulmonary fibrosis (IPF) diagnosis in UK primary care
|
|
670
|
|
|
‡a
Author's Hormonal contraception and the risk of severe asthma exacerbation: 17-year population-based cohort study
|
|
670
|
|
|
‡a
Author's Hormonal contraceptives and onset of asthma in reproductive-age women: Population-based cohort study
|
|
670
|
|
|
‡a
Author's Hormone Replacement Therapy and Asthma Onset in Menopausal Women: National Cohort Study
|
|
670
|
|
|
‡a
Author's How to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze
|
|
670
|
|
|
‡a
Author's Identifying Patient Attitudinal Clusters Associated With Asthma Control: The European REALISE Survey
|
|
670
|
|
|
‡a
Author's Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative.
|
|
670
|
|
|
‡a
Author's Identifying the hidden burden of allergic rhinitis
|
|
670
|
|
|
‡a
Author's Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon.
|
|
670
|
|
|
‡a
Author's IgE-mediated asthma: New revelations and future insights
|
|
670
|
|
|
‡a
Author's Impact of allergic rhinitis on the day-to-day lives of children: insights from an Australian cross-sectional study
|
|
670
|
|
|
‡a
Author's Impact of comorbidities on asthma
|
|
670
|
|
|
‡a
Author's Impact of night-time symptoms in COPD: a real-world study in five European countries.
|
|
670
|
|
|
‡a
Author's Impact of Rhinitis on Work Productivity: A Systematic Review
|
|
670
|
|
|
‡a
Author's Impacts of coexisting bronchial asthma on severe exacerbations in mild-to-moderate COPD: results from a national database.
|
|
670
|
|
|
‡a
Author's Implementing the change in National Institute for Health and Clinical Excellence guidance on airflow obstruction grading in chronic obstructive pulmonary disease.
|
|
670
|
|
|
‡a
Author's Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study
|
|
670
|
|
|
‡a
Author's Improvement of asthma control with a breath-actuated pressurised metred dose inhaler
|
|
670
|
|
|
‡a
Author's Improvement of asthma control with a breath-actuated pressurised metred dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-actuated device.
|
|
670
|
|
|
‡a
Author's Improving clinical reality in chronic obstructive pulmonary disease economic modelling: development and validation of a micro-simulation approach.
|
|
670
|
|
|
‡a
Author's Improving clinician-patient communication in asthma: the HARP project
|
|
670
|
|
|
‡a
Author's Improving outcomes for asthma patients with allergic rhinitis: conclusions from the MetaForum conferences
|
|
670
|
|
|
‡a
Author's Improving outcomes for asthma patients with allergic rhinitis: the MetaForum conferences
|
|
670
|
|
|
‡a
Author's Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care.
|
|
670
|
|
|
‡a
Author's Inappropriate asthma therapy-a tale of two countries: a parallel population-based cohort study
|
|
670
|
|
|
‡a
Author's Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device
|
|
670
|
|
|
‡a
Author's Increased Dose of Inhaled Corticosteroid versus Add-On Long-acting β-Agonist for Step-Up Therapy in Asthma
|
|
670
|
|
|
‡a
Author's Inhalation by design: novel ultra-long-acting β
|
|
670
|
|
|
‡a
Author's Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.
|
|
670
|
|
|
‡a
Author's Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD
|
|
670
|
|
|
‡a
Author's Inhaled Corticosteroid Adherence Patterns in a Longitudinal Asthma Cohort
|
|
670
|
|
|
‡a
Author's Inhaled corticosteroid dose-response on blood eosinophils in asthma - Authors' reply.
|
|
670
|
|
|
‡a
Author's Inhaled corticosteroid/long-acting β₂-agonist combination therapy for asthma: attitudes of specialists in Europe
|
|
670
|
|
|
‡a
Author's Inhaled Corticosteroids and Placebo Treatment Effects in Adult Patients With Cough: A Systematic Review and Meta-analysis
|
|
670
|
|
|
‡a
Author's Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control
|
|
670
|
|
|
‡a
Author's Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study
|
|
670
|
|
|
‡a
Author's Inhaler competence in asthma: common errors, barriers to use and recommended solutions.
|
|
670
|
|
|
‡a
Author's Inhaler devices for asthma: a call for action in a neglected field
|
|
670
|
|
|
‡a
Author's Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
|
|
670
|
|
|
‡a
Author's Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes
|
|
670
|
|
|
‡a
Author's Inhaler technique mastery and maintenance in healthcare professionals trained on different devices.
|
|
670
|
|
|
‡a
Author's Initial step-up treatment changes in asthmatic children already prescribed inhaled corticosteroids: a historical cohort study
|
|
670
|
|
|
‡a
Author's Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation.
|
|
670
|
|
|
‡a
Author's Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada
|
|
670
|
|
|
‡a
Author's Integrating evidence for managing asthma in patients who smoke
|
|
670
|
|
|
‡a
Author's Integrating real-life studies in the global therapeutic research framework.
|
|
670
|
|
|
‡a
Author's Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial
|
|
670
|
|
|
‡a
Author's International consensus on (ICON) pediatric asthma
|
|
670
|
|
|
‡a
Author's InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients--the LIAISON study protocol
|
|
670
|
|
|
‡a
Author's International Primary Care Respiratory Group (IPCRG) Guidelines: diagnosis of respiratory diseases in primary care
|
|
670
|
|
|
‡a
Author's International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis
|
|
670
|
|
|
‡a
Author's International severe asthma registry (ISAR): protocol for a global registry
|
|
670
|
|
|
‡a
Author's Is living in a rural area good for your respiratory health? Results from a cross-sectional study in Scotland
|
|
670
|
|
|
‡a
Author's Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?
|
|
670
|
|
|
‡a
Author's It is important to distinguish between HFrEF and HFpEF when interpreting these data
|
|
670
|
|
|
‡a
Author's LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
|
|
670
|
|
|
‡a
Author's Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination therapy in Australia
|
|
670
|
|
|
‡a
Author's Lessons learnt from a primary care asthma improvement project
|
|
670
|
|
|
‡a
Author's LETTER TO THE EDITOR
|
|
670
|
|
|
‡a
Author's Leukotriene antagonists as first-line or add-on asthma-controller therapy.
|
|
670
|
|
|
‡a
Author's Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide
|
|
670
|
|
|
‡a
Author's Long-Acting β-Agonist in Combination or Separate Inhaler as Step-Up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids
|
|
670
|
|
|
‡a
Author's Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.
|
|
670
|
|
|
‡a
Author's Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT
|
|
670
|
|
|
‡a
Author's MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
|
|
670
|
|
|
‡a
Author's Management of allergic rhinitis in the community pharmacy: identifying the reasons behind medication self-selection
|
|
670
|
|
|
‡a
Author's Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety
|
|
670
|
|
|
‡a
Author's Management Of Community-Acquired Pneumonia: An Observational Study In UK Primary Care
|
|
670
|
|
|
‡a
Author's Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns
|
|
670
|
|
|
‡a
Author's Managing asthma in the era of biological therapies
|
|
670
|
|
|
‡a
Author's Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks
|
|
670
|
|
|
‡a
Author's Matching Inhaler Devices with Patients: The Role of the Primary Care Physician.
|
|
670
|
|
|
‡a
Author's Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases.
|
|
670
|
|
|
‡a
Author's Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study.
|
|
670
|
|
|
‡a
Author's Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over
|
|
670
|
|
|
‡a
Author's Mobile phone technology in the management of asthma
|
|
670
|
|
|
‡a
Author's Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication.
|
|
670
|
|
|
‡a
Author's Monitoring asthma in childhood: symptoms, exacerbations and quality of life
|
|
670
|
|
|
‡a
Author's Monitoring asthma in children
|
|
670
|
|
|
‡a
Author's MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis
|
|
670
|
|
|
‡a
Author's MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study
|
|
670
|
|
|
‡a
Author's MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety
|
|
670
|
|
|
‡a
Author's Multi-component assessment of chronic obstructive pulmonary disease: an evaluation of the ADO and DOSE indices and the global obstructive lung disease categories in international primary care data sets.
|
|
670
|
|
|
‡a
Author's Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK.
|
|
670
|
|
|
‡a
Author's New horizons in early stage COPD--improving knowledge, detection and treatment.
|
|
670
|
|
|
‡a
Author's Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence
|
|
670
|
|
|
‡a
Author's Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases
|
|
670
|
|
|
‡a
Author's Not all asthma inhalers are the same: factors to consider when prescribing an inhaler
|
|
670
|
|
|
‡a
Author's Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design
|
|
670
|
|
|
‡a
Author's Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma.
|
|
670
|
|
|
‡a
Author's Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study.
|
|
670
|
|
|
‡a
Author's Occupational asthma in a new employee.
|
|
670
|
|
|
‡a
Author's Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber
|
|
670
|
|
|
‡a
Author's Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort
|
|
670
|
|
|
‡a
Author's Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study
|
|
670
|
|
|
‡a
Author's P07 - Treatment load in the therapy management of allergic rhinitis: a UK retrospective database study
|
|
670
|
|
|
‡a
Author's Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial
|
|
670
|
|
|
‡a
Author's Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler
|
|
670
|
|
|
‡a
Author's Patient reported burden of asthma on resource use and productivity across 11 countries in Europe
|
|
670
|
|
|
‡a
Author's Pediatric asthma: an unmet need for more effective, focused treatments
|
|
670
|
|
|
‡a
Author's Perceptions, attitudes, and behaviours of Short-acting Beta2 Agonist users: an Australian cross-sectional community pharmacy-based study
|
|
670
|
|
|
‡a
Author's Perceptions, impact and management of asthma in South Africa: a patient questionnaire study
|
|
670
|
|
|
‡a
Author's Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire data
|
|
670
|
|
|
‡a
Author's Personalising care of adults with asthma from Asia: a modified e-Delphi consensus study to inform management tailored to attitude and control profiles
|
|
670
|
|
|
‡a
Author's Personalising care of adults with asthma from Asia: a modified e-Dephi consensus study to inform management tailored to attitude and control profiles
|
|
670
|
|
|
‡a
Author's Pharmacoeconomics of asthma treatment
|
|
670
|
|
|
‡a
Author's Physician-prescribed Asthma Treatment Regimen does not differ Between Smoking and Non-smoking Patients With Asthma in Seoul and Gyunggi province of Korea
|
|
670
|
|
|
‡a
Author's Physicians' attitudes towards combination therapy with inhaled corticosteroids and long-acting β2-agonists: an observational study in UK specialist care
|
|
670
|
|
|
‡a
Author's Physiological predictors Of peak inspiRatory flow using Observed lung function resultS
|
|
670
|
|
|
‡a
Author's Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation
|
|
670
|
|
|
‡a
Author's Physiotherapy breathing retraining for asthma: a randomised controlled trial.
|
|
670
|
|
|
‡a
Author's Point-of-care biomarkers in asthma management: Time to move forward
|
|
670
|
|
|
‡a
Author's Poor communication may impair optimal asthma care: a qualitative study
|
|
670
|
|
|
‡a
Author's Potential severe asthma hidden in UK primary care
|
|
670
|
|
|
‡a
Author's Practical guide to skin prick tests in allergy to aeroallergens.
|
|
670
|
|
|
‡a
Author's Practice development plans to improve the primary care management of acute asthma: randomised controlled trial
|
|
670
|
|
|
‡a
Author's Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice
|
|
670
|
|
|
‡a
Author's Predicting frequent COPD exacerbations using primary care data
|
|
670
|
|
|
‡a
Author's Predictive value of control of COPD for risk of exacerbations: An international, prospective study
|
|
670
|
|
|
‡a
Author's Predictors of asthma control in everyday clinical practice in Switzerland
|
|
670
|
|
|
‡a
Author's Prenatal antibiotic exposure and subsequent atopy
|
|
670
|
|
|
‡a
Author's Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study
|
|
670
|
|
|
‡a
Author's Prescribing trends in asthma: a longitudinal observational study
|
|
670
|
|
|
‡a
Author's Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach.
|
|
670
|
|
|
‡a
Author's Present and future management of asthma and COPD: proceedings from WONCA 1998
|
|
670
|
|
|
‡a
Author's Prevalence and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices
|
|
670
|
|
|
‡a
Author's Pro-con debate: Inhaled corticosteroids should not be prescribed in primary care to children under two years of age - the case for
|
|
670
|
|
|
‡a
Author's Professional and patient attitudes to using mobile phone technology to monitor asthma: questionnaire survey.
|
|
670
|
|
|
‡a
Author's Progressive breathlessness in COPD - the role of hyperinflation and its pharmacological management.
|
|
670
|
|
|
‡a
Author's Prospective observational study in patients with obstructive lung disease: NOVELTY design
|
|
670
|
|
|
‡a
Author's Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations.
|
|
670
|
|
|
‡a
Author's Quality standards for real-world research. Focus on observational database studies of comparative effectiveness
|
|
670
|
|
|
‡a
Author's Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool
|
|
670
|
|
|
‡a
Author's Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force
|
|
670
|
|
|
‡a
Author's Questions for COPD diagnostic screening in a primary care setting
|
|
670
|
|
|
‡a
Author's Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
|
|
670
|
|
|
‡a
Author's Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma
|
|
670
|
|
|
‡a
Author's Real-life effectiveness and safety of salbutamol Steri-Neb™ vs. Ventolin Nebules® for exacerbations in patients with COPD: Historical cohort study
|
|
670
|
|
|
‡a
Author's Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma: a historical cohort study using a US health claims database
|
|
670
|
|
|
‡a
Author's Real‐life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred‐dose inhalers in patients with asthma treated with ICS/LABA
|
|
670
|
|
|
‡a
Author's Real-Life Outcomes for Patients with Asthma Prescribed Spacers for Use with Either Extrafine- or Fine-Particle Inhaled Corticosteroids
|
|
670
|
|
|
‡a
Author's Real-life treatment of rhinitis in Australia: a historical cohort study of prescription and over-the-counter therapies for patients with and without additional respiratory disease
|
|
670
|
|
|
‡a
Author's Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
|
|
670
|
|
|
‡a
Author's Real-world perceptions of inhaled corticosteroid/long-acting β2-agonist combinations in the treatment of asthma
|
|
670
|
|
|
‡a
Author's Real-world research and its importance in respiratory medicine
|
|
670
|
|
|
‡a
Author's Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness
|
|
670
|
|
|
‡a
Author's Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease.
|
|
670
|
|
|
‡a
Author's Reducing the hidden burden of severe asthma: recognition and referrals from primary practice
|
|
670
|
|
|
‡a
Author's REG study: Real-life, longitudinal ICS adherence patterns in a UK asthma population
|
|
670
|
|
|
‡a
Author's Relationship of inhaled corticosteroid adherence to asthma exacerbations in patients with moderate to severe asthma.
|
|
670
|
|
|
‡a
Author's Reply
|
|
670
|
|
|
‡a
Author's Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA).
|
|
670
|
|
|
‡a
Author's Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank
|
|
670
|
|
|
‡a
Author's Respiratory effectiveness group study: Predictors of frequent severe asthma exacerbations
|
|
670
|
|
|
‡a
Author's Respiratory Medication Adherence: Toward a Common Language and a Shared Vision
|
|
670
|
|
|
‡a
Author's Rhinology Future Debates 2017 by EUFOREA: Novel treatments and surgical solutions in rhinology
|
|
670
|
|
|
‡a
Author's Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids
|
|
670
|
|
|
‡a
Author's Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients
|
|
670
|
|
|
‡a
Author's Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD.
|
|
670
|
|
|
‡a
Author's Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease.
|
|
670
|
|
|
‡a
Author's Routine telephone review of asthma: Authors' reply
|
|
670
|
|
|
‡a
Author's Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis
|
|
670
|
|
|
‡a
Author's Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life
|
|
670
|
|
|
‡a
Author's Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database
|
|
670
|
|
|
‡a
Author's Scoring system and clinical application of COPD diagnostic questionnaires
|
|
670
|
|
|
‡a
Author's Screening for and early detection of chronic obstructive pulmonary disease
|
|
670
|
|
|
‡a
Author's Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study.
|
|
670
|
|
|
‡a
Author's Setting the standard for routine asthma consultations: a discussion of the aims, process and outcomes of reviewing people with asthma in primary care.
|
|
670
|
|
|
‡a
Author's Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma
|
|
670
|
|
|
‡a
Author's Severe chronic allergic
|
|
670
|
|
|
‡a
Author's Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper
|
|
670
|
|
|
‡a
Author's Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis.
|
|
670
|
|
|
‡a
Author's Short-course montelukast for intermittent asthma in children: a randomized controlled trial
|
|
670
|
|
|
‡a
Author's Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety
|
|
670
|
|
|
‡a
Author's Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma.
|
|
670
|
|
|
‡a
Author's Spirometry: an essential tool for screening, case-finding, and diagnosis of COPD.
|
|
670
|
|
|
‡a
Author's Spirometry in primary care case-identification, diagnosis and management of COPD
|
|
670
|
|
|
‡a
Author's Standardized training for healthcare professionals and its impact on patients with perennial rhinitis: a multi-centre randomized controlled trial.
|
|
670
|
|
|
‡a
Author's Sub-optimal patient and physician communication in primary care consultations: its relation to severe and difficult asthma
|
|
670
|
|
|
‡a
Author's Suboptimal persistence with inhaled corticosteroid monotherapy among children with persistent asthma in the UK
|
|
670
|
|
|
‡a
Author's Switching patients from other inhaled corticosteroid devices to the Easyhaler(®): historical, matched-cohort study of real-life asthma patients
|
|
670
|
|
|
‡a
Author's Symptom-based questionnaire for differentiating COPD and asthma
|
|
670
|
|
|
‡a
Author's Symptom-based questionnaire for identifying COPD in smokers.
|
|
670
|
|
|
‡a
Author's Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management
|
|
670
|
|
|
‡a
Author's Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies
|
|
670
|
|
|
‡a
Author's Taking Aim at Asthma Around the World: Global Results of the Asthma Insight and Management Survey in the Asia-Pacific Region, Latin America, Europe, Canada, and the United States
|
|
670
|
|
|
‡a
Author's Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST
|
|
670
|
|
|
‡a
Author's The allergic allergist behaves like a patient
|
|
670
|
|
|
‡a
Author's The arch conference declaration. Helping to further the science of pragmatic research
|
|
670
|
|
|
‡a
Author's The Asthma Control Test
|
|
670
|
|
|
‡a
Author's The Asthma Control Test (ACT) as an alternative tool to Global Initiative for Asthma (GINA) guideline criteria for assessing asthma control in Vietnamese outpatients
|
|
670
|
|
|
‡a
Author's The Asthma Control TestTM
|
|
670
|
|
|
‡a
Author's The Asthma Control TestTM (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey
|
|
670
|
|
|
‡a
Author's The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care
|
|
670
|
|
|
‡a
Author's The BREATHE study: Breathing REtraining for Asthma--Trial of Home Exercises. a protocol summary of a randomised controlled trial.
|
|
670
|
|
|
‡a
Author's The Brussels Declaration: the need for change in asthma management
|
|
670
|
|
|
‡a
Author's The burden of paediatric asthma is higher than health professionals think: results from the Asthma in Real Life (AIR) study
|
|
670
|
|
|
‡a
Author's The Burden of Rhinitis and the Impact of Medication Management within the Community Pharmacy Setting
|
|
670
|
|
|
‡a
Author's The Burden of Self-Reported Rhinitis and Associated Risk for Exacerbations with Moderate-Severe Asthma in Primary Care Patients
|
|
670
|
|
|
‡a
Author's The challenge of recruiting in primary care for a trial of telemonitoring in asthma: an observational study
|
|
670
|
|
|
‡a
Author's The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study
|
|
670
|
|
|
‡a
Author's The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study
|
|
670
|
|
|
‡a
Author's The current burden of allergic rhinitis amongst primary care practitioners and its impact on patient management
|
|
670
|
|
|
‡a
Author's The CYMPLA trial. Mobile phone-based strrctrred intervention to achieve asthma control in patients with rncontrolled persistent asthma: a pragmatic randomised controlled trial
|
|
670
|
|
|
‡a
Author's The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship
|
|
670
|
|
|
‡a
Author's The effect of smoking on exacerbation risk in eosinophilic patients with COPD.
|
|
670
|
|
|
‡a
Author's The feasibility of recruiting patients with early COPD to a pilot trial assessing the effects of a physical activity intervention
|
|
670
|
|
|
‡a
Author's The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey
|
|
670
|
|
|
‡a
Author's The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK
|
|
670
|
|
|
‡a
Author's The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis
|
|
670
|
|
|
‡a
Author's The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.
|
|
670
|
|
|
‡a
Author's The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline
|
|
670
|
|
|
‡a
Author's The national montelukast survey
|
|
670
|
|
|
‡a
Author's The pharmacoepidemiology of COPD: recent advances and methodological discussion.
|
|
670
|
|
|
‡a
Author's The prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients: a protocol for an UNLOCK study from the IPCRG.
|
|
670
|
|
|
‡a
Author's The prevalence of dysfunctional breathing in adults in the community with and without asthma
|
|
670
|
|
|
‡a
Author's The REal Life EVidence AssessmeNt Tool
|
|
670
|
|
|
‡a
Author's The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies
|
|
670
|
|
|
‡a
Author's The Relationship Between 24-Hour Symptoms and COPD Exacerbations and Healthcare Resource Use: Results from an Observational Study (ASSESS).
|
|
670
|
|
|
‡a
Author's The Relationship Between Real-World Inhaled Corticosteroid Adherence and Asthma Outcomes: A Multilevel Approach
|
|
670
|
|
|
‡a
Author's The Role of Aeroallergen Sensitization Testing in Asthma Management
|
|
670
|
|
|
‡a
Author's The UK General Practice Airways Group (GPIAG): its formation, development, and influence on the management of asthma and other respiratory diseases over the last twenty years.
|
|
670
|
|
|
‡a
Author's The use of a modification of the Patient Enablement Instrument in asthma
|
|
670
|
|
|
‡a
Author's The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes.
|
|
670
|
|
|
‡a
Author's The use of omalizumab in asthma.
|
|
670
|
|
|
‡a
Author's The use of roflumilast in COPD: a primary care perspective
|
|
670
|
|
|
‡a
Author's The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control.
|
|
670
|
|
|
‡a
Author's The way forward: dry powder inhalers should only be switched with physician agreement and patient training.
|
|
670
|
|
|
‡a
Author's Three little words: an empirical test of the optimum scoring method for the RCP 3 questions
|
|
670
|
|
|
‡a
Author's Time for a new language for asthma control: results from REALISE Asia
|
|
670
|
|
|
‡a
Author's Tolerability of montelukast.
|
|
670
|
|
|
‡a
Author's Treatment Adherence in Adolescents with Asthma
|
|
670
|
|
|
‡a
Author's Treatment and outcomes in patients with asthma and allergic rhinitis in the United kingdom.
|
|
670
|
|
|
‡a
Author's Treatment patterns among non-active users of maintenance asthma medication in the United Kingdom: a retrospective cohort study in the Clinical Practice Research Datalink
|
|
670
|
|
|
‡a
Author's Trends of testing for and diagnosis of α 1 -antitrypsin deficiency in the UK: more testing is needed
|
|
670
|
|
|
‡a
Author's "Trying, But Failing" - The Role of Inhaler Technique and Mode of Delivery in Respiratory Medication Adherence
|
|
670
|
|
|
‡a
Author's Types, frequency and impact of asthma triggers on patients' lives: a quantitative study in five European countries
|
|
670
|
|
|
‡a
Author's UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study
|
|
670
|
|
|
‡a
Author's Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey
|
|
670
|
|
|
‡a
Author's Understanding the potential role of mobile phone-based monitoring on asthma self-management: qualitative study
|
|
670
|
|
|
‡a
Author's Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease
|
|
670
|
|
|
‡a
Author's UNLOCK: Uncovering and Noting Long-term Outcomes in COPD to enhance knowledge
|
|
670
|
|
|
‡a
Author's Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy.
|
|
670
|
|
|
‡a
Author's Urinary prostanoids in preschool wheeze.
|
|
670
|
|
|
‡a
Author's Use of electronic medical records and biomarkers to manage risk and resource efficiencies
|
|
670
|
|
|
‡a
Author's Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial
|
|
670
|
|
|
‡a
Author's Using fractional exhaled nitric oxide
|
|
670
|
|
|
‡a
Author's Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care
|
|
670
|
|
|
‡a
Author's Validating the Concept of COPD Control: A Real-world Cohort Study from the United Kingdom.
|
|
670
|
|
|
‡a
Author's Variation in Demographic and Clinical Characteristics of Patients with COPD Receiving Care in US Primary Care: Data from the Advancing the Patient EXperience (APEX) in COPD Registry
|
|
670
|
|
|
‡a
Author's What happens to patients who have their asthma device switched without their consent?
|
|
670
|
|
|
‡a
Author's What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion
|
|
670
|
|
|
‡a
Author's What We Mean When We Talk About Adherence in Respiratory Medicine.
|
|
670
|
|
|
‡a
Author's What we should learn from the London Olympics
|
|
670
|
|
|
‡a
Author's Work productivity in rhinitis using cell phones: The MASK pilot study
|
|
670
|
|
|
‡a
Author's XXIV World Allergy Congress 2015
|
|
670
|
|
|
‡a
Author's XXIV World Allergy Congress 2015: Seoul, Korea. 14-17 October 2015
|
|
670
|
|
|
‡a
Author's প্রত্যুত্তর
|
|
670
|
|
|
‡a
Author's সম্পাদককে চিঠি
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/viaf/173084525
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/processed/LC|nb2011018587
|
|
909
|
|
|
‡a
(scopus) 55629533100
‡9
1
|
|
909
|
|
|
‡a
(orcid) 000000021195039x
‡9
1
|
|
909
|
|
|
‡a
(orcid) 0000000297289992
‡9
1
|
|
912
|
|
|
‡a
lettertotheeditor
‡A
LETTER TO THE EDITOR
‡9
1
|
|
912
|
|
|
‡a
ariadigitalanamorphosisdigitaltransformationofhealthandcareinairwaydiseasesfromresearchtopractice
‡A
ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice
‡9
1
|
|
912
|
|
|
‡a
reply
‡A
Reply
‡9
1
|
|
919
|
|
|
‡a
devicetypeandrealworldeffectivenessofasthmacombinationtherapyanobservationalstudy
‡A
Device type and real-world effectiveness of asthma combination therapy: An observational study
‡9
1
|
|
919
|
|
|
‡a
europeanpositionpaperonrhinosinusitisandnasalpolyps
‡A
European Position Paper on Rhinosinusitis and Nasal Polyps 2012.
‡9
1
|
|
919
|
|
|
‡a
achievingasthmacontrolinpracticeunderstandingthereasonsforpoorcontrol
‡A
Achieving asthma control in practice: understanding the reasons for poor control
‡9
1
|
|
919
|
|
|
‡a
achievingoptimalasthmacontrolcanthisbeinformedbyrecentstudiesofprofessionalpatientcommunication
‡A
Achieving optimal asthma control: Can this be informed by recent studies of professional-patient communication?
‡9
1
|
|
919
|
|
|
‡a
addonlabainaseparateinhalerasasthmastepuptherapyversusincreaseddoseoficsoricslabacombinationinhaler
‡A
Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
‡9
1
|
|
919
|
|
|
‡a
internationalcrosssectionalandlongitudinalassessmentonasthmacontrolineuropeanadultpatientstheliaisonstudyprotocol
‡A
InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients--the LIAISON study protocol
‡9
1
|
|
919
|
|
|
‡a
asthmacontroltest
‡A
The Asthma Control Test
‡9
1
|
|
919
|
|
|
‡a
archconferencedeclarationhelpingtofurtherthescienceofpragmaticresearch
‡A
The arch conference declaration. Helping to further the science of pragmatic research
‡9
1
|
|
919
|
|
|
‡a
allergicallergistbehaveslikeapatient
‡A
The allergic allergist behaves like a patient
‡9
1
|
|
919
|
|
|
‡a
adequacyoftherapyforpeoplewithbothcopdandheartfailureintheukhistoricalcohortstudy
‡A
Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study
‡9
1
|
|
919
|
|
|
‡a
temporarilyquadruplingthedoseofinhaledsteroidtopreventasthmaexacerbationsfast
‡A
Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST
‡9
1
|
|
919
|
|
|
‡a
takingaimatasthmaaroundtheworldglobalresultsoftheasthmainsightandmanagementsurveyintheasiapacificregionlatinamericaeuropecanadaandtheunitedstates
‡A
Taking Aim at Asthma Around the World: Global Results of the Asthma Insight and Management Survey in the Asia-Pacific Region, Latin America, Europe, Canada, and the United States
‡9
1
|
|
919
|
|
|
‡a
systemsmedicineapproachesforthedefinitionofcomplexphenotypesinchronicdiseasesandageingfromconcepttoimplementationandpolicies
‡A
Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies
‡9
1
|
|
919
|
|
|
‡a
systematicliteraturereviewofsystemiccorticosteroiduseforasthmamanagement
‡A
Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management
‡9
1
|
|
919
|
|
|
‡a
symptombasedquestionnaireforidentifyingcopdinsmokers
‡A
Symptom-based questionnaire for identifying COPD in smokers.
‡9
1
|
|
919
|
|
|
‡a
tryingbutfailingtheroleofinhalertechniqueandmodeofdeliveryinrespiratorymedicationadherence
‡A
"Trying, But Failing" - The Role of Inhaler Technique and Mode of Delivery in Respiratory Medication Adherence
‡9
1
|
|
919
|
|
|
‡a
europeansymposiumonprecisionmedicineinallergyandairwaysdiseasesreportoftheeuropeanunionparliamentsymposiumoctober14
‡A
European Symposium on Precision Medicine in Allergy and Airways Diseases: Report of the European Union Parliament Symposium (October 14, 2015).
‡9
1
|
|
919
|
|
|
‡a
erratumtoeffectivenessofinitiatingextrafineparticleversusfineparticleinhaledcorticosteroidsasasthmatherapyinthenetherlands
‡A
Erratum to: Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands
‡9
1
|
|
919
|
|
|
‡a
internationalprimarycarerespiratorygroupipcrgguidelinesdiagnosisofrespiratorydiseasesinprimarycare
‡A
International Primary Care Respiratory Group (IPCRG) Guidelines: diagnosis of respiratory diseases in primary care
‡9
1
|
|
919
|
|
|
‡a
erratumpredictingfrequentcopdexacerbationsusingprimarycaredata
‡A
Erratum: Predicting frequent COPD exacerbations using primary care data [Corrigendum]
‡9
1
|
|
919
|
|
|
‡a
erratumclinicalimpactandhealthcareresourceutilizationassociatedwithearlyversuslatecopddiagnosisinpatientsfromukcprddatabase
‡A
Erratum: Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database [Corrigendum]
‡9
1
|
|
919
|
|
|
‡a
erratumchangesininitialcopdtreatmentchoiceovertimeandfactorsinfluencingprescribingdecisionsinukprimarycarearealworldstudy
‡A
Erratum: Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study
‡9
1
|
|
919
|
|
|
‡a
adjunctivetreatmentwithoralakl1abotanicalnutraceuticalinchronicobstructivepulmonarydisease
‡A
Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease
‡9
1
|
|
919
|
|
|
‡a
adjustableandfixeddosingwithbudesonideformoterolviaasingleinhalerinasthmapatientstheassurestudy
‡A
Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study
‡9
1
|
|
919
|
|
|
‡a
internationalprimarycarerespiratorygroupipcrgguidelinesmanagementofallergicrhinitis
‡A
International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis
‡9
1
|
|
919
|
|
|
‡a
itisimportanttodistinguishbetweenhfrefandhfpefwheninterpretingthesedata
‡A
It is important to distinguish between HFrEF and HFpEF when interpreting these data
‡9
1
|
|
919
|
|
|
‡a
istherearationaleandroleforlongactinganticholinergicbronchodilatorsinasthma
‡A
Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?
‡9
1
|
|
919
|
|
|
‡a
internationalsevereasthmaregistryisarprotocolforaglobalregistry
‡A
International severe asthma registry (ISAR): protocol for a global registry
‡9
1
|
|
919
|
|
|
‡a
igemediatedasthmanewrevelationsandfutureinsights
‡A
IgE-mediated asthma: New revelations and future insights
‡9
1
|
|
919
|
|
|
‡a
advancesinpharmacotherapyforthetreatmentofallergicrhinitismp2902anovelformulationofazelastinehydrochlorideandfluticasonepropionateinanadvanceddeliverysystemfillsthegaps
‡A
Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
‡9
1
|
|
919
|
|
|
‡a
advancingthepatientexperienceapexincopdregistrystudydesignandstrengths
‡A
Advancing the Patient EXperience (APEX) in COPD Registry: Study Design and Strengths
‡9
1
|
|
919
|
|
|
‡a
adverseoutcomesfrominitiationofsystemiccorticosteroidsforasthmalongtermobservationalstudy
‡A
Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study
‡9
1
|
|
919
|
|
|
‡a
ageandsexassociationswithsystemiccorticosteroidinducedmorbidityinasthma
‡A
Age and Sex Associations with Systemic Corticosteroid-Induced Morbidity in Asthma
‡9
1
|
|
919
|
|
|
‡a
newtherapy
‡A
A new therapy
‡9
1
|
|
919
|
|
|
‡a
newefficacyparametercompletenearcompletesymptomreliefinallergicrhinitismanagementresultswithanewtherapymp2902
‡A
A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*.
‡9
1
|
|
919
|
|
|
‡a
newefficacyparameter
‡A
A new efficacy parameter
‡9
1
|
|
919
|
|
|
‡a
multinationalobservationalstudyidentifyingprimarycarepatientsatriskofoverestimationofasthmacontrol
‡A
A multinational observational study identifying primary care patients at risk of overestimation of asthma control
‡9
1
|
|
919
|
|
|
‡a
comparisonofthereallifeclinicaleffectivenessoftheleadinglicensedicslabacombinationinhalersinthetreatmentforcopd
‡A
A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD
‡9
1
|
|
919
|
|
|
‡a
commonlanguagetoassessallergicrhinitiscontrolresultsfromasurveyconductedduringeaaci2013congress
‡A
A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
‡9
1
|
|
919
|
|
|
‡a
boldstatementonhowtocasefindmoderateseverecopd
‡A
A BOLD statement on how to case-find moderate/severe COPD.
‡9
1
|
|
919
|
|
|
‡a
2016respiratoryeffectivenessgroupannualsummitreportimpactandinfluenceofrealworldrespiratoryevidence
‡A
2016 Respiratory Effectiveness Group Annual Summit Report-impact & influence of real-world respiratory evidence.
‡9
1
|
|
919
|
|
|
‡a
useoflowdoseoraltheophyllineasanadjuncttoinhaledcorticosteroidsinpreventingexacerbationsofchronicobstructivepulmonarydiseasestudyprotocolforarandomisedcontrolledtrial
‡A
Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial
‡9
1
|
|
919
|
|
|
‡a
islivinginaruralareagoodforyourrespiratoryhealthresultsfromacrosssectionalstudyinscotland
‡A
Is living in a rural area good for your respiratory health? Results from a cross-sectional study in Scotland
‡9
1
|
|
919
|
|
|
‡a
impactofallergicrhinitisonthedaytodaylivesofchildreninsightsfromanaustraliancrosssectionalstudy
‡A
Impact of allergic rhinitis on the day-to-day lives of children: insights from an Australian cross-sectional study
‡9
1
|
|
919
|
|
|
‡a
impactofcomorbiditiesonasthma
‡A
Impact of comorbidities on asthma
‡9
1
|
|
919
|
|
|
‡a
allergicrhinitisandasthmasymptomsinareallifestudyofmpazeflutotreatmultimorbidallergicrhinitisandasthma
‡A
Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
‡9
1
|
|
919
|
|
|
‡a
urinaryprostanoidsinpreschoolwheeze
‡A
Urinary prostanoids in preschool wheeze.
‡9
1
|
|
919
|
|
|
‡a
allergicrhinitisanditsimpactonasthma
‡A
Allergic Rhinitis and its Impact on Asthma
‡9
1
|
|
919
|
|
|
‡a
leukotrieneantagonistsas1lineoraddonasthmacontrollertherapy
‡A
Leukotriene antagonists as first-line or add-on asthma-controller therapy.
‡9
1
|
|
919
|
|
|
‡a
usingfractionalexhalednitricoxide
‡A
Using fractional exhaled nitric oxide
‡9
1
|
|
919
|
|
|
‡a
definitionsofsevereanddifficultasthmabyagroupofukgeneralpractitioners
‡A
Definitions of severe and difficult asthma by a group of UK general practitioners
‡9
1
|
|
919
|
|
|
‡a
definingsevereobstructivelungdiseaseinthebiologiceraanendotypebasedapproach
‡A
Defining severe obstructive lung disease in the biologic era: an endotype-based approach
‡9
1
|
|
919
|
|
|
‡a
reallifeevidenceassessmenttool
‡A
The REal Life EVidence AssessmeNt Tool
‡9
1
|
|
919
|
|
|
‡a
prevalenceofdysfunctionalbreathinginadultsinthecommunitywithandwithoutasthma
‡A
The prevalence of dysfunctional breathing in adults in the community with and without asthma
‡9
1
|
|
919
|
|
|
‡a
asthmacontroltestactasanalternativetooltoglobalinitiativeforasthmaginaguidelinecriteriaforassessingasthmacontrolinvietnameseoutpatients
‡A
The Asthma Control Test (ACT) as an alternative tool to Global Initiative for Asthma (GINA) guideline criteria for assessing asthma control in Vietnamese outpatients
‡9
1
|
|
919
|
|
|
‡a
impactofnighttimesymptomsincopdarealworldstudyin5europeancountries
‡A
Impact of night-time symptoms in COPD: a real-world study in five European countries.
‡9
1
|
|
919
|
|
|
‡a
relationshipbetweenrealworldinhaledcorticosteroidadherenceandasthmaoutcomesamultilevelapproach
‡A
The Relationship Between Real-World Inhaled Corticosteroid Adherence and Asthma Outcomes: A Multilevel Approach
‡9
1
|
|
919
|
|
|
‡a
urgingeuropetoputnonadherencetoinhaledrespiratorymedicationhigheronthepolicyagendaareportfromthe1europeancongressonadherencetotherapy
‡A
Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy.
‡9
1
|
|
919
|
|
|
‡a
unlockuncoveringandnotinglongtermoutcomesincopdtoenhanceknowledge
‡A
UNLOCK: Uncovering and Noting Long-term Outcomes in COPD to enhance knowledge
‡9
1
|
|
919
|
|
|
‡a
useofroflumilastincopdaprimarycareperspective
‡A
The use of roflumilast in COPD: a primary care perspective
‡9
1
|
|
919
|
|
|
‡a
roleofaeroallergensensitizationtestinginasthmamanagement
‡A
The Role of Aeroallergen Sensitization Testing in Asthma Management
‡9
1
|
|
919
|
|
|
‡a
symptombasedquestionnairefordifferentiatingcopdandasthma
‡A
Symptom-based questionnaire for differentiating COPD and asthma
‡9
1
|
|
919
|
|
|
‡a
switchingpatientsfromotherinhaledcorticosteroiddevicestotheeasyhalerhistoricalmatchedcohortstudyofreallifeasthmapatients
‡A
Switching patients from other inhaled corticosteroid devices to the Easyhaler(®): historical, matched-cohort study of real-life asthma patients
‡9
1
|
|
919
|
|
|
‡a
prevalenceofcomorbiditiesincopdpatientsandtheirimpactonhealthstatusandcopdsymptomsinprimarycarepatientsaprotocolforanunlockstudyfromtheipcrg
‡A
The prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients: a protocol for an UNLOCK study from the IPCRG.
‡9
1
|
|
919
|
|
|
‡a
suboptimalpersistencewithinhaledcorticosteroidmonotherapyamongchildrenwithpersistentasthmaintheuk
‡A
Suboptimal persistence with inhaled corticosteroid monotherapy among children with persistent asthma in the UK
‡9
1
|
|
919
|
|
|
‡a
suboptimalpatientandphysiciancommunicationinprimarycareconsultationsitsrelationtosevereanddifficultasthma
‡A
Sub-optimal patient and physician communication in primary care consultations: its relation to severe and difficult asthma
‡9
1
|
|
919
|
|
|
‡a
asthmacontroltesttm
‡A
The Asthma Control TestTM
‡9
1
|
|
919
|
|
|
‡a
standardizedtrainingforhealthcareprofessionalsanditsimpactonpatientswithperennialrhinitisamulticentrerandomizedcontrolledtrial
‡A
Standardized training for healthcare professionals and its impact on patients with perennial rhinitis: a multi-centre randomized controlled trial.
‡9
1
|
|
919
|
|
|
‡a
pharmacoepidemiologyofcopdrecentadvancesandmethodologicaldiscussion
‡A
The pharmacoepidemiology of COPD: recent advances and methodological discussion.
‡9
1
|
|
919
|
|
|
‡a
ukgeneralpracticeairwaysgroupgpiagitsformationdevelopmentandinfluenceonthemanagementofasthmaandotherrespiratorydiseasesoverthelast20years
‡A
The UK General Practice Airways Group (GPIAG): its formation, development, and influence on the management of asthma and other respiratory diseases over the last twenty years.
‡9
1
|
|
919
|
|
|
‡a
useofamodificationofthepatientenablementinstrumentinasthma
‡A
The use of a modification of the Patient Enablement Instrument in asthma
‡9
1
|
|
919
|
|
|
‡a
allergicrhinitisanditsimpactonasthmaariaachievementsin10yearsandfutureneeds
‡A
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs
‡9
1
|
|
919
|
|
|
‡a
allergicrhinitisanditsimpactonasthmaariaguidelines2016revision
‡A
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision
‡9
1
|
|
919
|
|
|
‡a
economicevaluationofadjustableandfixeddosingwithbudesonideformoterolviaasingleinhalerinasthmapatientstheassurestudy
‡A
An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study
‡9
1
|
|
919
|
|
|
‡a
spirometryinprimarycarecaseidentificationdiagnosisandmanagementofcopd
‡A
Spirometry in primary care case-identification, diagnosis and management of COPD
‡9
1
|
|
919
|
|
|
‡a
economicevaluationofnioxminoairwayinflammationmonitorintheunitedkingdom
‡A
An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom
‡9
1
|
|
919
|
|
|
‡a
spirometryanessentialtoolforscreeningcasefindinganddiagnosisofcopd
‡A
Spirometry: an essential tool for screening, case-finding, and diagnosis of COPD.
‡9
1
|
|
919
|
|
|
‡a
smallparticleinhaledcorticosteroidas1lineorstepupcontrollertherapyinchildhoodasthma
‡A
Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma.
‡9
1
|
|
919
|
|
|
‡a
shortcoursesystemiccorticosteroidsinasthmastrikingthebalancebetweenefficacyandsafety
‡A
Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety
‡9
1
|
|
919
|
|
|
‡a
shortcoursemontelukastforintermittentasthmainchildrenarandomizedcontrolledtrial
‡A
Short-course montelukast for intermittent asthma in children: a randomized controlled trial
‡9
1
|
|
919
|
|
|
‡a
shortandlongtermsafetyofmp2902anewtherapyforthetreatmentofallergicrhinitis
‡A
Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis.
‡9
1
|
|
919
|
|
|
‡a
databasestudiesinasthmapharmacoeconomicsuseslimitationsandqualitymarkers
‡A
Database studies in asthma pharmacoeconomics: uses, limitations and quality markers
‡9
1
|
|
919
|
|
|
‡a
useofmultiplerespiratoryinhalersrequiringdifferentinhalationtechniqueshasanadverseeffectoncopdoutcomes
‡A
The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes.
‡9
1
|
|
919
|
|
|
‡a
useofomalizumabinasthma
‡A
The use of omalizumab in asthma.
‡9
1
|
|
919
|
|
|
‡a
currentevidenceandfutureresearchneedsforfenomeasurementinrespiratorydiseases
‡A
Current evidence and future research needs for FeNO measurement in respiratory diseases
‡9
1
|
|
919
|
|
|
‡a
evaluationofexactmatchingandpropensityscoremethodsasappliedinacomparativeeffectivenessstudyofinhaledcorticosteroidsinasthma
‡A
An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma
‡9
1
|
|
919
|
|
|
‡a
exploratorypragmaticclusterrandomisedtrialofpracticenursetrainingintheuseofasthmaactionplans
‡A
An exploratory, pragmatic, cluster randomised trial of practice nurse training in the use of asthma action plans.
‡9
1
|
|
919
|
|
|
‡a
innovativecorticosteroidlongactingβ2agonistbreathtriggeredinhalerfacilitatinglungdeliveryoffluticasonepropionateformoterolfumarateforthetreatmentofasthma
‡A
An innovative corticosteroid/long-acting β2-agonist breath-triggered inhaler: facilitating lung delivery of fluticasone propionate/formoterol fumarate for the treatment of asthma
‡9
1
|
|
919
|
|
|
‡a
severechronicallergicandrelateddiseasesauniformapproachamedallga2lenariapositionpaper
‡A
Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper
‡9
1
|
|
919
|
|
|
‡a
antibioticprescribingandoutcomesoflowerrespiratorytractinfectioninukprimarycare
‡A
Antibiotic prescribing and outcomes of lower respiratory tract infection in UK primary care.
‡9
1
|
|
919
|
|
|
‡a
applyingukrealworldprimarycaredatatopredictasthmaattacksin3776wellcharacterisedchildrenaretrospectivecohortstudy
‡A
Applying UK real-world primary care data to predict asthma attacks in 3776 well-characterised children: a retrospective cohort study
‡9
1
|
|
919
|
|
|
‡a
arepharmacologicalrandomisedcontrolledclinicaltrialsrelevanttoreallifeasthmapopulationsaprotocolforanunlockstudyfromtheipcrg
‡A
Are pharmacological randomised controlled clinical trials relevant to real-life asthma populations? A protocol for an UNLOCK study from the IPCRG.
‡9
1
|
|
919
|
|
|
‡a
impactofrhinitisonworkproductivityasystematicreview
‡A
Impact of Rhinitis on Work Productivity: A Systematic Review
‡9
1
|
|
919
|
|
|
‡a
usingfractionalexhalednitricoxidefenotodiagnosesteroidresponsivediseaseandguideasthmamanagementinroutinecare
‡A
Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care
‡9
1
|
|
919
|
|
|
‡a
impactsofcoexistingbronchialasthmaonsevereexacerbationsinmildtomoderatecopdresultsfromanationaldatabase
‡A
Impacts of coexisting bronchial asthma on severe exacerbations in mild-to-moderate COPD: results from a national database.
‡9
1
|
|
919
|
|
|
‡a
implementingthechangeinnationalinstituteforhealthandclinicalexcellenceguidanceonairflowobstructiongradinginchronicobstructivepulmonarydisease
‡A
Implementing the change in National Institute for Health and Clinical Excellence guidance on airflow obstruction grading in chronic obstructive pulmonary disease.
‡9
1
|
|
919
|
|
|
‡a
improvedadherencewith11dailyversustwicedailydosingofmometasonefuroateadministeredviaadrypowderinhalerarandomizedopenlabelstudy
‡A
Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study
‡9
1
|
|
919
|
|
|
‡a
currentcontroversiesandchallengesinallergicrhinitismanagement
‡A
Current controversies and challenges in allergic rhinitis management
‡9
1
|
|
919
|
|
|
‡a
severechronicallergic
‡A
Severe chronic allergic
‡9
1
|
|
919
|
|
|
‡a
currentcontrolandfutureriskinasthmamanagement
‡A
Current control and future risk in asthma management
‡9
1
|
|
919
|
|
|
‡a
severeasthmaglobalevaluationsageanelectronicplatformforsevereasthma
‡A
Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma
‡9
1
|
|
919
|
|
|
‡a
ariaupdate1systematicreviewofcomplementaryandalternativemedicineforrhinitisandasthma
‡A
ARIA update: I--Systematic review of complementary and alternative medicine for rhinitis and asthma
‡9
1
|
|
919
|
|
|
‡a
improvementofasthmacontrolwithabreathactuatedpressurisedmetreddoseinhaler
‡A
Improvement of asthma control with a breath-actuated pressurised metred dose inhaler
‡9
1
|
|
919
|
|
|
‡a
couldinterchangeableuseofdrypowderinhalersaffectpatients
‡A
Could interchangeable use of dry powder inhalers affect patients?
‡9
1
|
|
919
|
|
|
‡a
settingthestandardforroutineasthmaconsultationsadiscussionoftheaimsprocessandoutcomesofreviewingpeoplewithasthmainprimarycare
‡A
Setting the standard for routine asthma consultations: a discussion of the aims, process and outcomes of reviewing people with asthma in primary care.
‡9
1
|
|
919
|
|
|
‡a
timeforanewlanguageforasthmacontrolresultsfromrealiseasia
‡A
Time for a new language for asthma control: results from REALISE Asia
‡9
1
|
|
919
|
|
|
‡a
seasonalpatternsoforalantihistamineandintranasalcorticosteroidpurchasesfromaustraliancommunitypharmaciesaretrospectiveobservationalstudy
‡A
Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study.
‡9
1
|
|
919
|
|
|
‡a
asthmacontroltesttmactasapredictorofginaguidelinedefinedasthmacontrolanalysisofamultinationalcrosssectionalsurvey
‡A
The Asthma Control TestTM (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey
‡9
1
|
|
919
|
|
|
‡a
nationalmontelukastsurvey
‡A
The national montelukast survey
‡9
1
|
|
919
|
|
|
‡a
longtermburdenofcopdexacerbationsduringmaintenancetherapyandlungfunctiondecline
‡A
The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline
‡9
1
|
|
919
|
|
|
‡a
evaluationofinhalertechniqueandachievementandmaintenanceofmasteryofbudesonideformoterolspiromaxcomparedwithbudesonideformoterolturbuhalerinadultpatientswithasthmatheeasylowinstructionovertimeeliotstudy
‡A
Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study.
‡9
1
|
|
919
|
|
|
‡a
developmentoftheinternationalsevereasthmaregistryisaramodifieddelphistudy
‡A
Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study
‡9
1
|
|
919
|
|
|
‡a
highdoseinhaledcorticosteroidsversusaddonlongactingbetaagonistsinasthmaanobservationalstudy
‡A
High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: an observational study
‡9
1
|
|
919
|
|
|
‡a
developmentoftheinternationalsevereasthmaregistry
‡A
Development of the International Severe Asthma Registry
‡9
1
|
|
919
|
|
|
‡a
screeningforandearlydetectionofchronicobstructivepulmonarydisease
‡A
Screening for and early detection of chronic obstructive pulmonary disease
‡9
1
|
|
919
|
|
|
‡a
scoringsystemandclinicalapplicationofcopddiagnosticquestionnaires
‡A
Scoring system and clinical application of COPD diagnostic questionnaires
‡9
1
|
|
919
|
|
|
‡a
evaluatingthereallifeeffectofmpazefluonasthmaoutcomesinpatientswithallergicrhinitisandasthmainukprimarycare
‡A
Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
‡9
1
|
|
919
|
|
|
‡a
accessibilityacceptabilityandeffectivenessinprimarycareofroutinetelephonereviewofasthmapragmaticrandomisedcontrolledtrial
‡A
Accessibility, acceptability, and effectiveness in primary care of routine telephone review of asthma: pragmatic, randomised controlled trial
‡9
1
|
|
919
|
|
|
‡a
salmeterolxinafoateananalysisofoutcomesandcosteffectivenessusingaprimarycaredatabase
‡A
Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database
‡9
1
|
|
919
|
|
|
‡a
salmeterolfluticasonestabledosetreatmentcomparedwithformoterolbudesonideadjustablemaintenancedosingimpactonhealthrelatedqualityoflife
‡A
Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life
‡9
1
|
|
919
|
|
|
‡a
safetyevaluationofmp2902anovelintranasalformulationofazelastinehydrochlorideandfluticasonepropionateforallergicrhinitis
‡A
Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis
‡9
1
|
|
919
|
|
|
‡a
developmentoftheadvancingthepatientexperienceincopdregistryamodifieddelphistudy
‡A
Development of the Advancing the Patient Experience in COPD Registry: A Modified Delphi Study
‡9
1
|
|
919
|
|
|
‡a
routinetelephonereviewofasthmaauthorsreply
‡A
Routine telephone review of asthma: Authors' reply
‡9
1
|
|
919
|
|
|
‡a
roleofclinicalquestionnairesinoptimizingeverydaycareofchronicobstructivepulmonarydisease
‡A
Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease.
‡9
1
|
|
919
|
|
|
‡a
costutilityanalysisofindacaterolingermanya11dailymaintenancebronchodilatorforpatientswithcopd
‡A
Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
‡9
1
|
|
919
|
|
|
‡a
developmentofaprimarycaretooltoassesstreatmentsuccessincopdconsensusreportfromaclosedmeetingofrespiratoryandprimarycarespecialists
‡A
Development of a primary-care tool to assess treatment success in COPD: consensus report from a closed meeting of respiratory and primary-care specialists
‡9
1
|
|
919
|
|
|
‡a
risktobenefitratioofinhaledcorticosteroidsinpatientswithcopd
‡A
Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD.
‡9
1
|
|
919
|
|
|
‡a
riskpredictorsandsymptomfeaturesoflongcovidwithinabroadprimarycarepatientpopulationincludingbothtestedanduntestedpatients
‡A
Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients
‡9
1
|
|
919
|
|
|
‡a
historicalcohortstudyexaminingcomparativeeffectivenessofalbuterolinhalerswithandwithoutintegrateddosecounterforpatientswithasthmaorchronicobstructivepulmonarydisease
‡A
Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease
‡9
1
|
|
919
|
|
|
‡a
costeffectivenessofthelongactingβ2adrenergicagonistlabalongactingmuscarinicantagonistdualbronchodilatorindacaterolglycopyrroniumversusthelabainhaledcorticosteroidcombinationsalmeterolfluticasoneinpatientswithchronicob
‡A
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Ob
‡9
1
|
|
919
|
|
|
‡a
costeffectivenessofthelongactingβ2adrenergicagonist
‡A
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist
‡9
1
|
|
919
|
|
|
‡a
evaluationofcriteriaforclinicalcontrolinaprospectiveinternationalmulticenterstudyofpatientswithcopd
‡A
Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD
‡9
1
|
|
919
|
|
|
‡a
longactingmuscarinicantagonistuseinadultswithasthmareallifeprescribingandoutcomesofaddontherapywithtiotropiumbromide
‡A
Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide
‡9
1
|
|
919
|
|
|
‡a
longactingβagonistincombinationorseparateinhalerasstepuptherapyforchildrenwithuncontrolledasthmareceivinginhaledcorticosteroids
‡A
Long-Acting β-Agonist in Combination or Separate Inhaler as Step-Up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids
‡9
1
|
|
919
|
|
|
‡a
historicaldatabasecohortstudyaddressingtheclinicalpatternspriortoidiopathicpulmonaryfibrosisipfdiagnosisinukprimarycare
‡A
Historical database cohort study addressing the clinical patterns prior to idiopathic pulmonary fibrosis (IPF) diagnosis in UK primary care
‡9
1
|
|
919
|
|
|
‡a
evaluationofinhalertechniqueandachievementandmaintenanceofmasteryofbudesonideformoterolspiromaxcomparedwithbudesonideformoterolturbuhalerinadultpatientswithasthmatheeasylowinstructionovertime
‡A
Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time
‡9
1
|
|
919
|
|
|
‡a
trendsoftestingforanddiagnosisofα1antitrypsindeficiencyintheukmoretestingisneeded
‡A
Trends of testing for and diagnosis of α 1 -antitrypsin deficiency in the UK: more testing is needed
‡9
1
|
|
919
|
|
|
‡a
eposprimarycareguidelineseuropeanpositionpaperontheprimarycarediagnosisandmanagementofrhinosinusitisandnasalpolyps2007asummary
‡A
EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007 - a summary.
‡9
1
|
|
919
|
|
|
‡a
epos2012europeanpositionpaperonrhinosinusitisandnasalpolyps2012asummaryforotorhinolaryngologists
‡A
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists
‡9
1
|
|
919
|
|
|
‡a
eligibilityofreallifepatientswithcopdforinclusionintrialsofinhaledlongactingbronchodilatortherapy
‡A
Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
‡9
1
|
|
919
|
|
|
‡a
electronicclinicaldecisionsupportsystemforallergicrhinitismanagementmaskecdss
‡A
Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSS
‡9
1
|
|
919
|
|
|
‡a
highdoseinhaledcorticosteroidsandaddontherapyuseinadultswithasthmaintheukin2003anobservationalstudy
‡A
High-dose inhaled corticosteroids and add-on therapy use in adults with asthma in the UK in 2003: an observational study
‡9
1
|
|
919
|
|
|
‡a
developmentandvalidationofanattitudinalprofilingtoolforpatientswithasthma
‡A
Development and Validation of an Attitudinal-Profiling Tool for Patients With Asthma
‡9
1
|
|
919
|
|
|
‡a
improvementofasthmacontrolwithabreathactuatedpressurisedmetreddoseinhalerbaiaprescribingclaimsstudyof5556patientsusingatraditionalpressurisedmetreddoseinhaler1501orabreathactuateddevice
‡A
Improvement of asthma control with a breath-actuated pressurised metred dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-actuated device.
‡9
1
|
|
919
|
|
|
‡a
relationshipbetween24hoursymptomsandcopdexacerbationsandhealthcareresourceuseresultsfromanobservationalstudyassess
‡A
The Relationship Between 24-Hour Symptoms and COPD Exacerbations and Healthcare Resource Use: Results from an Observational Study (ASSESS).
‡9
1
|
|
919
|
|
|
‡a
riskofpneumoniainobstructivelungdiseaseareallifestudycomparingextrafineandfineparticleinhaledcorticosteroids
‡A
Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids
‡9
1
|
|
919
|
|
|
‡a
rhinologyfuturedebates2017byeuforeanoveltreatmentsandsurgicalsolutionsinrhinology
‡A
Rhinology Future Debates 2017 by EUFOREA: Novel treatments and surgical solutions in rhinology
‡9
1
|
|
919
|
|
|
‡a
respiratorymedicationadherencetowardacommonlanguageandasharedvision
‡A
Respiratory Medication Adherence: Toward a Common Language and a Shared Vision
‡9
1
|
|
919
|
|
|
‡a
highdoseinhaledcorticosteroiduseinchildhoodasthmaanobservationalstudyofgpprescribing
‡A
High-dose inhaled corticosteroid use in childhood asthma: an observational study of GP prescribing
‡9
1
|
|
919
|
|
|
‡a
respiratoryeffectivenessgroupstudypredictorsoffrequentsevereasthmaexacerbations
‡A
Respiratory effectiveness group study: Predictors of frequent severe asthma exacerbations
‡9
1
|
|
919
|
|
|
‡a
efficacyversuseffectivenesstrialsinformingguidelinesforasthmamanagement
‡A
Efficacy versus effectiveness trials: informing guidelines for asthma management
‡9
1
|
|
919
|
|
|
‡a
researchprioritiesinpediatricasthmaresultsofaglobalsurveyofmultiplestakeholdergroupsbythepediatricasthmainreallifepearlthinktank
‡A
Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank
‡9
1
|
|
919
|
|
|
‡a
requirementsformedicationscommonlyusedinthetreatmentofallergicrhinitiseuropeanacademyofallergyandclinicalimmunologyeaaciallergicrhinitisanditsimpactonasthmaaria
‡A
Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA).
‡9
1
|
|
919
|
|
|
‡a
relationshipofinhaledcorticosteroidadherencetoasthmaexacerbationsinpatientswithmoderatetosevereasthma
‡A
Relationship of inhaled corticosteroid adherence to asthma exacerbations in patients with moderate to severe asthma.
‡9
1
|
|
919
|
|
|
‡a
regstudyreallifelongitudinalicsadherencepatternsinaukasthmapopulation
‡A
REG study: Real-life, longitudinal ICS adherence patterns in a UK asthma population
‡9
1
|
|
919
|
|
|
‡a
reducingthehiddenburdenofsevereasthmarecognitionandreferralsfromprimarypractice
‡A
Reducing the hidden burden of severe asthma: recognition and referrals from primary practice
‡9
1
|
|
919
|
|
|
‡a
redefiningcutpointsforhighsymptomburdenoftheglobalinitiativeforchronicobstructivelungdiseaseclassificationin18577patientswithchronicobstructivepulmonarydisease
‡A
Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease.
‡9
1
|
|
919
|
|
|
‡a
reassessingtheevidencehierarchyinasthmaevaluatingcomparativeeffectiveness
‡A
Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness
‡9
1
|
|
919
|
|
|
‡a
realworldresearchanditsimportanceinrespiratorymedicine
‡A
Real-world research and its importance in respiratory medicine
‡9
1
|
|
919
|
|
|
‡a
realworldperceptionsofinhaledcorticosteroidlongactingβ2agonistcombinationsinthetreatmentofasthma
‡A
Real-world perceptions of inhaled corticosteroid/long-acting β2-agonist combinations in the treatment of asthma
‡9
1
|
|
919
|
|
|
‡a
reallifeevidenceassessmenttoolrelevantdevelopmentofanovelqualityassuranceassettorateobservationalcomparativeeffectivenessresearchstudies
‡A
The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies
‡9
1
|
|
919
|
|
|
‡a
assessingtheclinicalvalueoffastonsetandsustaineddurationofactionoflongactingbronchodilatorsforcopd
‡A
Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD.
‡9
1
|
|
919
|
|
|
‡a
associationbetweenbloodeosinophilcountandriskofreadmissionforpatientswithasthmahistoricalcohortstudy
‡A
Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study
‡9
1
|
|
919
|
|
|
‡a
improvingclinicalrealityinchronicobstructivepulmonarydiseaseeconomicmodellingdevelopmentandvalidationofamicrosimulationapproach
‡A
Improving clinical reality in chronic obstructive pulmonary disease economic modelling: development and validation of a micro-simulation approach.
‡9
1
|
|
919
|
|
|
‡a
associationbetweencopdexacerbationsandlungfunctiondeclineduringmaintenancetherapy
‡A
Association between COPD exacerbations and lung function decline during maintenance therapy
‡9
1
|
|
919
|
|
|
‡a
hormonalcontraceptionandtheriskofsevereasthmaexacerbation17yearpopulationbasedcohortstudy
‡A
Hormonal contraception and the risk of severe asthma exacerbation: 17-year population-based cohort study
‡9
1
|
|
919
|
|
|
‡a
hormonalcontraceptivesandonsetofasthmainreproductiveagewomenpopulationbasedcohortstudy
‡A
Hormonal contraceptives and onset of asthma in reproductive-age women: Population-based cohort study
‡9
1
|
|
919
|
|
|
‡a
associationofelevatedfractionalexhalednitricoxideconcentrationandbloodeosinophilcountwithsevereasthmaexacerbations
‡A
Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
‡9
1
|
|
919
|
|
|
‡a
asthmaacrossageinsightsfromprimarycare
‡A
Asthma Across Age: Insights From Primary Care
‡9
1
|
|
919
|
|
|
‡a
asthmaandallergicrhinitislinkedintreatmentandoutcomes
‡A
Asthma and allergic rhinitis: Linked in treatment and outcomes
‡9
1
|
|
919
|
|
|
‡a
asthmaatriskregisterscanbeeffectiveifcarefullyconstructedandcorrectlyimplemented
‡A
Asthma at-risk registers--can be effective if carefully constructed and correctly implemented
‡9
1
|
|
919
|
|
|
‡a
longtermrandomizedsafetystudyofmp2902anovelintranasalformulationofazelastinehydrochlorideandfluticasonepropionateinanadvanceddeliverysysteminsubjectswithchronicrhinitis
‡A
Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.
‡9
1
|
|
919
|
|
|
‡a
asthmacontrolandmanagementin8000europeanpatientstherecogniseasthmaandlinktosymptomsandexperiencerealisesurvey
‡A
Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey
‡9
1
|
|
919
|
|
|
‡a
developmentandimplementationofguidelinesinallergicrhinitisanariaga2lenpaper
‡A
Development and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paper
‡9
1
|
|
919
|
|
|
‡a
efficacyoffluticasonepropionateformoterolfumarateinthetreatmentofasthmaapooledanalysis
‡A
Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: a pooled analysis.
‡9
1
|
|
919
|
|
|
‡a
asthmacontrolwithextrafineparticlehydrofluoroalkanebeclometasonevslargeparticlechlorofluorocarbonbeclometasonearealworldobservationalstudy
‡A
Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study
‡9
1
|
|
919
|
|
|
‡a
lowdoseoraltheophyllinecombinedwithinhaledcorticosteroidsforpeoplewithchronicobstructivepulmonarydiseaseandhighriskofexacerbationsarct
‡A
Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT
‡9
1
|
|
919
|
|
|
‡a
asthmainasiaphysicianperspectivesoncontrolinhaleruseandpatientcommunications
‡A
Asthma in Asia: Physician perspectives on control, inhaler use and patient communications.
‡9
1
|
|
919
|
|
|
‡a
healthcareresourceutilizationandcostsassociatedwithincrementalsystemiccorticosteroidexposureinasthma
‡A
Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma
‡9
1
|
|
919
|
|
|
‡a
asthmaoutofcontrolastructuredreviewofrecentpatientsurveys
‡A
Asthma out of control? A structured review of recent patient surveys
‡9
1
|
|
919
|
|
|
‡a
healthcareresourceuseandcostsofsevereuncontrolledeosinophilicasthmaintheukgeneralpopulation
‡A
Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population
‡9
1
|
|
919
|
|
|
‡a
asthmaoutcomesandcostsoftherapywithextrafinebeclomethasoneandfluticasone
‡A
Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone
‡9
1
|
|
919
|
|
|
‡a
asthmareferralsakeycomponentofasthmamanagementthatneedstobeaddressed
‡A
Asthma referrals: a key component of asthma management that needs to be addressed
‡9
1
|
|
919
|
|
|
‡a
abs74largevariationsinasthmacontrolbetweenukgeneralpracticesparticipatingintheasthmacontrolconcordanceandtoleranceacctinitiative
‡A
ABS74: Large variations in asthma control between UK general practices participating in the asthma control, concordance and tolerance (ACCT) Initiative
‡9
1
|
|
919
|
|
|
‡a
asthmarelatedhealthcareresourceuseamongasthmaticchildrenwithandwithoutconcomitantallergicrhinitis
‡A
Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis
‡9
1
|
|
919
|
|
|
‡a
improvingclinicianpatientcommunicationinasthmatheharpproject
‡A
Improving clinician-patient communication in asthma: the HARP project
‡9
1
|
|
919
|
|
|
‡a
abs41montelukastas1linepreventativetreatmentforasthmainchildrenage25yrsaretrospectivestudy
‡A
ABS41: Montelukast as first-line preventative treatment for asthma in children age 2-5 yrs: A retrospective study
‡9
1
|
|
919
|
|
|
‡a
fourfoldasthmastudyfastastudyprotocolforarandomisedcontrolledtrialevaluatingtheclinicalcosteffectivenessoftemporarilyquadruplingthedoseofinhaledsteroidtopreventasthmaexacerbations
‡A
FourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations.
‡9
1
|
|
919
|
|
|
‡a
fourfoldasthmastudy
‡A
FourFold Asthma Study
‡9
1
|
|
919
|
|
|
‡a
fluticasonepropionateformoterolfumarateinfixeddosecombinationforthetreatmentofasthma
‡A
Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
‡9
1
|
|
919
|
|
|
‡a
asthmarelatedoutcomesinpatientsinitiatingextrafineciclesonideorfineparticleinhaledcorticosteroids
‡A
Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids
‡9
1
|
|
919
|
|
|
‡a
atriskregistersinsevereasthmaarrisastudyaclusterrandomisedcontrolledtrialexaminingeffectivenessandcostsinprimarycare
‡A
The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care
‡9
1
|
|
919
|
|
|
‡a
fluticasonepropionateanauditofoutcomesandcosteffectivenessinprimarycare
‡A
Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care
‡9
1
|
|
919
|
|
|
‡a
flawedcomparativegroupsleadtoflawedconclusionsresponse
‡A
Flawed Comparative Groups Lead to Flawed Conclusions: Response
‡9
1
|
|
919
|
|
|
‡a
efficacyandsafetyoftiotropiumincopdpatientsinprimarycarethespirivausualcaresprucestudy
‡A
Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study.
‡9
1
|
|
919
|
|
|
‡a
abs29thesmartplandevelopmentofasymptombasedasthmaactionplanforsingleinhalertherapy
‡A
ABS29: The SMART plan: development of a symptom-based asthma action plan for single inhaler therapy
‡9
1
|
|
919
|
|
|
‡a
1maintenancetherapyforcopdintheukbetween2009and2012aretrospectivedatabaseanalysis
‡A
First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis
‡9
1
|
|
919
|
|
|
‡a
fgf8morphogengradientsaredifferentiallyregulatedbyheparansulphotransferaseshs2standhs6st1inthedevelopingbrain
‡A
FGF8 morphogen gradients are differentially regulated by heparan sulphotransferases Hs2st and Hs6st1 in the developing brain
‡9
1
|
|
919
|
|
|
‡a
feasibilityandethics
‡A
Feasibility and ethics
‡9
1
|
|
919
|
|
|
‡a
factorsassociatedwithappropriateinhaleruseinpatientswithcopdlessonsfromtherealsurvey
‡A
Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey.
‡9
1
|
|
919
|
|
|
‡a
abs008asthmamanagementandthepcpfindingsoftheglobalasthmaphysicianandpatientgappsurvey
‡A
ABS008: Asthma management and the PCP: Findings of the global asthma physician and patient (GAPP) survey
‡9
1
|
|
919
|
|
|
‡a
breathestudybreathingretrainingforasthmatrialofhomeexercisesaprotocolsummaryofarandomisedcontrolledtrial
‡A
The BREATHE study: Breathing REtraining for Asthma--Trial of Home Exercises. a protocol summary of a randomised controlled trial.
‡9
1
|
|
919
|
|
|
‡a
brusselsdeclarationtheneedforchangeinasthmamanagement
‡A
The Brussels Declaration: the need for change in asthma management
‡9
1
|
|
919
|
|
|
‡a
extrafineversusfineinhaledcorticosteroidsinrelationtoasthmacontrolasystematicreviewandmetaanalysisofobservationalreallifestudies
‡A
Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies
‡9
1
|
|
919
|
|
|
‡a
macviaclinicaldecisionalgorithminadolescentsandadultswithallergicrhinitis
‡A
MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
‡9
1
|
|
919
|
|
|
‡a
managementofallergicrhinitisinthecommunitypharmacyidentifyingthereasonsbehindmedicationselfselection
‡A
Management of allergic rhinitis in the community pharmacy: identifying the reasons behind medication self-selection
‡9
1
|
|
919
|
|
|
‡a
managementofasthmainschoolagechildrenontherapymascotarandomiseddoubleblindplacebocontrolledparallelstudyofefficacyandsafety
‡A
Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety
‡9
1
|
|
919
|
|
|
‡a
burdenofpaediatricasthmaishigherthanhealthprofessionalsthinkresultsfromtheasthmainreallifeairstudy
‡A
The burden of paediatric asthma is higher than health professionals think: results from the Asthma in Real Life (AIR) study
‡9
1
|
|
919
|
|
|
‡a
burdenofrhinitisandtheimpactofmedicationmanagementwithinthecommunitypharmacysetting
‡A
The Burden of Rhinitis and the Impact of Medication Management within the Community Pharmacy Setting
‡9
1
|
|
919
|
|
|
‡a
extrafinebeclometasonedipropionateformoterolfumaratevsdoublebronchodilationtherapyinpatientswithcopdahistoricalrealworldnoninferioritystudy
‡A
Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study
‡9
1
|
|
919
|
|
|
‡a
exploringtheroleofquantitativefeedbackininhalertechniqueeducationaclusterrandomised2armparallelgrouprepeatedmeasuresstudy
‡A
Exploring the role of quantitative feedback in inhaler technique education: a cluster-randomised, two-arm, parallel-group, repeated-measures study
‡9
1
|
|
919
|
|
|
‡a
expertconsensusonthetaperingoforalcorticosteroidsforthetreatmentofasthmaadelphistudy
‡A
Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma: A Delphi Study
‡9
1
|
|
919
|
|
|
‡a
exogenoussexsteroidhormonesandasthmainfemalesprotocolforapopulationbasedretrospectivecohortstudyusingaukprimarycaredatabase
‡A
Exogenous sex steroid hormones and asthma in females: protocol for a population-based retrospective cohort study using a UK primary care database.
‡9
1
|
|
919
|
|
|
‡a
burdenofselfreportedrhinitisandassociatedriskforexacerbationswithmoderatesevereasthmainprimarycarepatients
‡A
The Burden of Self-Reported Rhinitis and Associated Risk for Exacerbations with Moderate-Severe Asthma in Primary Care Patients
‡9
1
|
|
919
|
|
|
‡a
exacerbationsofchronicobstructivepulmonarydiseaseapatientsperspective
‡A
Exacerbations of chronic obstructive pulmonary disease--a patients' perspective.
‡9
1
|
|
919
|
|
|
‡a
challengeofrecruitinginprimarycareforatrialoftelemonitoringinasthmaanobservationalstudy
‡A
The challenge of recruiting in primary care for a trial of telemonitoring in asthma: an observational study
‡9
1
|
|
919
|
|
|
‡a
managementofcommunityacquiredpneumoniaanobservationalstudyinukprimarycare
‡A
Management Of Community-Acquired Pneumonia: An Observational Study In UK Primary Care
‡9
1
|
|
919
|
|
|
‡a
managementofcopdintheukprimarycaresettingananalysisofreallifeprescribingpatterns
‡A
Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns
‡9
1
|
|
919
|
|
|
‡a
managingasthmaintheeraofbiologicaltherapies
‡A
Managing asthma in the era of biological therapies
‡9
1
|
|
919
|
|
|
‡a
labalamacombinationsversuslamamonotherapyorlabaicsincopdasystematicreviewandmetaanalysis
‡A
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
‡9
1
|
|
919
|
|
|
‡a
effectivenessofsameversusmixedasthmainhalerdevicesaretrospectiveobservationalstudyinprimarycare
‡A
Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care
‡9
1
|
|
919
|
|
|
‡a
comparativeeffectivenessofinitiatingfluticasonesalmeterolcombinationtherapyviapmdiversusdpiinreducingexacerbationsandtreatmentescalationincopdaukdatabasestudy
‡A
The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study
‡9
1
|
|
919
|
|
|
‡a
abs004theconceptprevalenceandconsequencesoflowtolerancetoicsinasthma
‡A
ABS004: The concept, prevalence and consequences of low tolerance to ICS in asthma
‡9
1
|
|
919
|
|
|
‡a
costeffectivenessofthelabalamadualbronchodilatorindacaterolglycopyrroniuminaswedishhealthcaresetting
‡A
Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting
‡9
1
|
|
919
|
|
|
‡a
costeffectivenessoftelephoneorsurgeryasthmareviewseconomicanalysisofarandomisedcontrolledtrial
‡A
Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial
‡9
1
|
|
919
|
|
|
‡a
whatwemeanwhenwetalkaboutadherenceinrespiratorymedicine
‡A
What We Mean When We Talk About Adherence in Respiratory Medicine.
‡9
1
|
|
919
|
|
|
‡a
costeffectivenessofsalmeterolxinafoatefluticasonepropionatecombinationinhalerinchronicasthma
‡A
Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma
‡9
1
|
|
919
|
|
|
‡a
asthmaspecifichealthrelatedqualityoflifeofpeopleingreatbritainanationalsurvey
‡A
Asthma-specific health-related quality of life of people in Great Britain: A national survey
‡9
1
|
|
919
|
|
|
‡a
effectivenessofmp2902forthetreatmentofallergicrhinitisinrealliferesultsfromanoninterventionalstudy
‡A
Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study
‡9
1
|
|
919
|
|
|
‡a
matchedcohortstudyoftherapeuticstrategiestopreventpreschoolwheezingasthmaattacks
‡A
Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks
‡9
1
|
|
919
|
|
|
‡a
whatisasthmacopdoverlapsyndrometowardsaconsensusdefinitionfromaroundtablediscussion
‡A
What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion
‡9
1
|
|
919
|
|
|
‡a
matchinginhalerdeviceswithpatientstheroleoftheprimarycarephysician
‡A
Matching Inhaler Devices with Patients: The Role of the Primary Care Physician.
‡9
1
|
|
919
|
|
|
‡a
costeffectivenessofchlorofluorocarbonfreebeclomethasonedipropionateinthetreatmentofchronicasthmaacostmodelbasedona1yearpragmaticrandomisedclinicalstudy
‡A
The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study
‡9
1
|
|
919
|
|
|
‡a
currentburdenofallergicrhinitisamongstprimarycarepractitionersanditsimpactonpatientmanagement
‡A
The current burden of allergic rhinitis amongst primary care practitioners and its impact on patient management
‡9
1
|
|
919
|
|
|
‡a
authorcorrectiontheimpactofpoorasthmacontrolamongasthmapatientstreatedwithinhaledcorticosteroidspluslongactingβ2agonistsintheunitedkingdomacrosssectionalanalysis
‡A
Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis
‡9
1
|
|
919
|
|
|
‡a
befriendingcarersofpeoplewithdementiaacostutilityanalysis
‡A
Befriending carers of people with dementia: a cost utility analysis
‡9
1
|
|
919
|
|
|
‡a
medicationrelatedcostsofrhinitisinaustraliaanostradatacrosssectionalstudyofpharmacypurchases
‡A
Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases.
‡9
1
|
|
919
|
|
|
‡a
cymplatrialmobilephonebasedstrrctrredinterventiontoachieveasthmacontrolinpatientswithrncontrolledpersistentasthmaapragmaticrandomisedcontrolledtrial
‡A
The CYMPLA trial. Mobile phone-based strrctrred intervention to achieve asthma control in patients with rncontrolled persistent asthma: a pragmatic randomised controlled trial
‡9
1
|
|
919
|
|
|
‡a
whathappenstopatientswhohavetheirasthmadeviceswitchedwithouttheirconsent
‡A
What happens to patients who have their asthma device switched without their consent?
‡9
1
|
|
919
|
|
|
‡a
befriendingcarersofpeoplewithdementiarandomisedcontrolledtrial
‡A
Befriending carers of people with dementia: randomised controlled trial
‡9
1
|
|
919
|
|
|
‡a
harmonizingthenomenclaturefortherapeuticaerosolparticlesizeaproposal
‡A
Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal
‡9
1
|
|
919
|
|
|
‡a
metaboliceffectsassociatedwithicsinpatientswithcopdandcomorbidtype2diabetesahistoricalmatchedcohortstudy
‡A
Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study.
‡9
1
|
|
919
|
|
|
‡a
misdiagnosisofcopdandasthmainprimarycarepatients40yearsofageandover
‡A
Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over
‡9
1
|
|
919
|
|
|
‡a
guidelinesforallergicrhinitisneedtobeusedinprimarycare
‡A
Guidelines for allergic rhinitis need to be used in primary care
‡9
1
|
|
919
|
|
|
‡a
bloodeosinophilcountandexacerbationriskinpatientswithcopd
‡A
Blood eosinophil count and exacerbation risk in patients with COPD.
‡9
1
|
|
919
|
|
|
‡a
underuseofβblockersinheartfailureandchronicobstructivepulmonarydisease
‡A
Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease
‡9
1
|
|
919
|
|
|
‡a
bloodeosinophilcountandprospectiveannualasthmadiseaseburdenaukcohortstudy
‡A
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
‡9
1
|
|
943
|
|
|
‡a
201x
‡A
2015
‡9
5
|
|
943
|
|
|
‡a
199x
‡A
1998
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
BIBSYS|2043878
|
|
996
|
|
|
‡2
ISNI|0000000449314051
|
|
996
|
|
|
‡2
BIBSYS|90188597
|
|
996
|
|
|
‡2
CAOONL|ncf12027893
|
|
996
|
|
|
‡2
ISNI|0000000367945255
|
|
996
|
|
|
‡2
LC|nb2002026902
|
|
996
|
|
|
‡2
LC|n 86842644
|
|
996
|
|
|
‡2
ISNI|0000000084717850
|
|
996
|
|
|
‡2
ISNI|0000000454168749
|
|
996
|
|
|
‡2
CAOONL|ncf10912894
|
|
996
|
|
|
‡2
SUDOC|154460419
|
|
996
|
|
|
‡2
LC|no2022041192
|
|
996
|
|
|
‡2
LNB|LNC10-000281779
|
|
996
|
|
|
‡2
NUKAT|n 2009096026
|
|
996
|
|
|
‡2
RERO|A003711630
|
|
996
|
|
|
‡2
NII|DA02243604
|
|
996
|
|
|
‡2
ISNI|0000000040884104
|
|
996
|
|
|
‡2
SUDOC|098196863
|
|
996
|
|
|
‡2
ISNI|0000000032126039
|
|
996
|
|
|
‡2
SUDOC|030645794
|
|
996
|
|
|
‡2
DNB|134488636
|
|
996
|
|
|
‡2
NII|DA04463419
|
|
996
|
|
|
‡2
LC|no2023004409
|
|
996
|
|
|
‡2
BNF|10251671
|
|
996
|
|
|
‡2
ISNI|0000000081731921
|
|
996
|
|
|
‡2
NII|DA06569090
|
|
996
|
|
|
‡2
NII|DA12514311
|
|
996
|
|
|
‡2
LC|n 78026907
|
|
996
|
|
|
‡2
SUDOC|257647155
|
|
996
|
|
|
‡2
DNB|14131138X
|
|
996
|
|
|
‡2
DNB|1232972576
|
|
996
|
|
|
‡2
ISNI|0000000040827054
|
|
996
|
|
|
‡2
LC|nb2015021131
|
|
996
|
|
|
‡2
NII|DA09877190
|
|
996
|
|
|
‡2
LC|no2003073294
|
|
996
|
|
|
‡2
ISNI|0000000078995272
|
|
996
|
|
|
‡2
LC|n 2008044468
|
|
996
|
|
|
‡2
CAOONL|ncf11930296
|
|
996
|
|
|
‡2
NTA|071320938
|
|
996
|
|
|
‡2
LC|nb2001069977
|
|
996
|
|
|
‡2
B2Q|0000830889
|
|
996
|
|
|
‡2
BNF|13808535
|
|
996
|
|
|
‡2
LC|no2012016069
|
|
996
|
|
|
‡2
LC|no2024068093
|
|
996
|
|
|
‡2
DNB|141311371
|
|
996
|
|
|
‡2
LC|nb2003061944
|
|
996
|
|
|
‡2
ISNI|0000000021278897
|
|
996
|
|
|
‡2
ISNI|0000000455716102
|
|
996
|
|
|
‡2
J9U|987007266767605171
|
|
996
|
|
|
‡2
LC|nb2015019549
|
|
996
|
|
|
‡2
LC|n 95115991
|
|
996
|
|
|
‡2
NTA|135558476
|
|
996
|
|
|
‡2
DBC|87097969654096
|
|
996
|
|
|
‡2
LC|n 88192391
|
|
996
|
|
|
‡2
BIBSYS|90333603
|
|
996
|
|
|
‡2
NKC|mub2013740133
|
|
996
|
|
|
‡2
LC|no2020016708
|
|
996
|
|
|
‡2
NTA|24557686X
|
|
996
|
|
|
‡2
ISNI|000000045217335X
|
|
996
|
|
|
‡2
SUDOC|112185800
|
|
996
|
|
|
‡2
ISNI|0000000474352826
|
|
996
|
|
|
‡2
DNB|136532055
|
|
996
|
|
|
‡2
LC|n 85137062
|
|
996
|
|
|
‡2
LC|no2012006730
|
|
996
|
|
|
‡2
BIBSYS|90370377
|
|
996
|
|
|
‡2
ISNI|000000011390738X
|
|
996
|
|
|
‡2
BNC|981058616336906706
|
|
996
|
|
|
‡2
SUDOC|119668114
|
|
996
|
|
|
‡2
DNB|1119828562
|
|
996
|
|
|
‡2
NUKAT|n 2013002387
|
|
996
|
|
|
‡2
DNB|13034687X
|
|
996
|
|
|
‡2
LC|no2016013424
|
|
996
|
|
|
‡2
ISNI|0000000045896198
|
|
996
|
|
|
‡2
SUDOC|190733721
|
|
996
|
|
|
‡2
NKC|jo2016926307
|
|
996
|
|
|
‡2
NII|DA03095987
|
|
996
|
|
|
‡2
DNB|132028158
|
|
996
|
|
|
‡2
LC|nb2016025284
|
|
996
|
|
|
‡2
NDL|00453320
|
|
996
|
|
|
‡2
ISNI|0000000116108428
|
|
996
|
|
|
‡2
DNB|173501990
|
|
996
|
|
|
‡2
NKC|jn20010602440
|
|
996
|
|
|
‡2
LC|n 88155469
|
|
996
|
|
|
‡2
LC|no2001082911
|
|
996
|
|
|
‡2
J9U|987007340351105171
|
|
996
|
|
|
‡2
ISNI|0000000434963251
|
|
996
|
|
|
‡2
SUDOC|171184262
|
|
996
|
|
|
‡2
LC|nb2017017988
|
|
996
|
|
|
‡2
SUDOC|174599854
|
|
996
|
|
|
‡2
BIBSYS|9033097
|
|
996
|
|
|
‡2
ISNI|0000000496512720
|
|
996
|
|
|
‡2
LC|nb2015022262
|
|
996
|
|
|
‡2
LC|n 88218113
|
|
996
|
|
|
‡2
LC|no2008176381
|
|
996
|
|
|
‡2
BIBSYS|90073772
|
|
996
|
|
|
‡2
BNF|14522641
|
|
996
|
|
|
‡2
NUKAT|n 02032174
|
|
996
|
|
|
‡2
NTA|228127459
|
|
996
|
|
|
‡2
ISNI|000000036715391X
|
|
996
|
|
|
‡2
N6I|vtls001328367
|
|
996
|
|
|
‡2
BIBSYS|12037594
|
|
996
|
|
|
‡2
LC|n 82124649
|
|
996
|
|
|
‡2
J9U|987007364380805171
|
|
996
|
|
|
‡2
SUDOC|147291836
|
|
996
|
|
|
‡2
LC|nb2014020306
|
|
996
|
|
|
‡2
ISNI|000000011985504X
|
|
996
|
|
|
‡2
BNF|13775387
|
|
996
|
|
|
‡2
LC|n 2014188055
|
|
996
|
|
|
‡2
ISNI|0000000119546001
|
|
996
|
|
|
‡2
RERO|A003711628
|
|
996
|
|
|
‡2
LC|no 97035713
|
|
996
|
|
|
‡2
BAV|495_282991
|
|
996
|
|
|
‡2
SUDOC|25117297X
|
|
996
|
|
|
‡2
NKC|mzk20201093612
|
|
996
|
|
|
‡2
LC|n 77012636
|
|
996
|
|
|
‡2
NTA|069665427
|
|
996
|
|
|
‡2
NII|DA00533964
|
|
996
|
|
|
‡2
DNB|14040614X
|
|
996
|
|
|
‡2
NTA|190517409
|
|
996
|
|
|
‡2
SUDOC|156609673
|
|
996
|
|
|
‡2
PLWABN|9810571466605606
|
|
996
|
|
|
‡2
PLWABN|9810681294605606
|
|
996
|
|
|
‡2
ISNI|0000000036540202
|
|
996
|
|
|
‡2
NUKAT|n 99044521
|
|
996
|
|
|
‡2
LC|no2021132747
|
|
996
|
|
|
‡2
J9U|987007463135705171
|
|
996
|
|
|
‡2
BIBSYS|1041888
|
|
996
|
|
|
‡2
LC|no2015079151
|
|
996
|
|
|
‡2
BIBSYS|3069643
|
|
996
|
|
|
‡2
CAOONL|ncf11181492
|
|
996
|
|
|
‡2
J9U|987007327514805171
|
|
996
|
|
|
‡2
ISNI|000000002417556X
|
|
996
|
|
|
‡2
LC|no2021116895
|
|
996
|
|
|
‡2
DNB|141311320
|
|
996
|
|
|
‡2
BNE|XX1010707
|
|
996
|
|
|
‡2
BNF|12809727
|
|
996
|
|
|
‡2
LC|no 91016266
|
|
996
|
|
|
‡2
ISNI|0000000078903390
|
|
996
|
|
|
‡2
J9U|987007439929905171
|
|
996
|
|
|
‡2
BNF|12281953
|
|
996
|
|
|
‡2
BNF|15971129
|
|
996
|
|
|
‡2
ISNI|0000000401850576
|
|
996
|
|
|
‡2
J9U|987007314040405171
|
|
996
|
|
|
‡2
SUDOC|088785319
|
|
996
|
|
|
‡2
NII|DA12173811
|
|
996
|
|
|
‡2
NTA|269257829
|
|
996
|
|
|
‡2
NLA|000036035568
|
|
996
|
|
|
‡2
LC|n 2002135961
|
|
996
|
|
|
‡2
J9U|987007447119805171
|
|
996
|
|
|
‡2
SUDOC|031196195
|
|
996
|
|
|
‡2
BNF|14034587
|
|
996
|
|
|
‡2
LC|no2011148948
|
|
996
|
|
|
‡2
NTA|096585447
|
|
996
|
|
|
‡2
CAOONL|ncf11558987
|
|
996
|
|
|
‡2
ISNI|0000000108577929
|
|
996
|
|
|
‡2
NUKAT|n 2016198705
|
|
996
|
|
|
‡2
LC|n 2005006432
|
|
996
|
|
|
‡2
LC|no2019049433
|
|
996
|
|
|
‡2
CAOONL|ncf11344664
|
|
996
|
|
|
‡2
LC|n 2001109901
|
|
996
|
|
|
‡2
NTA|155721062
|
|
996
|
|
|
‡2
LC|n 50045773
|
|
996
|
|
|
‡2
LC|no2024124906
|
|
996
|
|
|
‡2
DNB|139140158
|
|
996
|
|
|
‡2
ISNI|0000000424482999
|
|
996
|
|
|
‡2
ISNI|0000000024540184
|
|
996
|
|
|
‡2
NUKAT|n 01041425
|
|
996
|
|
|
‡2
ISNI|0000000037160324
|
|
996
|
|
|
‡2
ISNI|0000000033504062
|
|
996
|
|
|
‡2
LC|no 98055672
|
|
996
|
|
|
‡2
SUDOC|230695116
|
|
996
|
|
|
‡2
SUDOC|114459363
|
|
996
|
|
|
‡2
CAOONL|ncf12029096
|
|
996
|
|
|
‡2
ISNI|0000000114692448
|
|
996
|
|
|
‡2
LC|n 92065063
|
|
996
|
|
|
‡2
DNB|1261492609
|
|
996
|
|
|
‡2
NII|DA03717996
|
|
996
|
|
|
‡2
J9U|987007322625705171
|
|
996
|
|
|
‡2
LC|no2017052880
|
|
996
|
|
|
‡2
LC|no2023075728
|
|
996
|
|
|
‡2
ISNI|0000000082081190
|
|
996
|
|
|
‡2
LC|no2013016861
|
|
996
|
|
|
‡2
CAOONL|ncf11332418
|
|
996
|
|
|
‡2
J9U|987007266767305171
|
|
996
|
|
|
‡2
ISNI|000000037463421X
|
|
996
|
|
|
‡2
LC|nr 97002169
|
|
996
|
|
|
‡2
J9U|987007355216605171
|
|
996
|
|
|
‡2
BNF|12276507
|
|
996
|
|
|
‡2
LC|n 78078555
|
|
996
|
|
|
‡2
NLA|000035387670
|
|
996
|
|
|
‡2
NII|DA00892810
|
|
996
|
|
|
‡2
CAOONL|ncf11333787
|
|
996
|
|
|
‡2
J9U|987007275943905171
|
|
996
|
|
|
‡2
LC|nr2001039737
|
|
996
|
|
|
‡2
NII|DA13649280
|
|
996
|
|
|
‡2
DNB|1057301000
|
|
996
|
|
|
‡2
ISNI|0000000436807957
|
|
996
|
|
|
‡2
LC|n 85031950
|
|
996
|
|
|
‡2
NTA|067597394
|
|
996
|
|
|
‡2
NTA|06850571X
|
|
996
|
|
|
‡2
J9U|987007348011105171
|
|
996
|
|
|
‡2
ISNI|0000000113754619
|
|
996
|
|
|
‡2
BIBSYS|90269031
|
|
996
|
|
|
‡2
ISNI|0000000074319509
|
|
996
|
|
|
‡2
LC|n 82127517
|
|
996
|
|
|
‡2
J9U|987007427666605171
|
|
996
|
|
|
‡2
NLA|000035485105
|
|
996
|
|
|
‡2
BIBSYS|1094380
|
|
996
|
|
|
‡2
SUDOC|02874604X
|
|
996
|
|
|
‡2
NTA|142075825
|
|
996
|
|
|
‡2
ISNI|0000000073034827
|
|
996
|
|
|
‡2
CAOONL|ncf10239950
|
|
996
|
|
|
‡2
BNF|12493290
|
|
996
|
|
|
‡2
SUDOC|06025288X
|
|
996
|
|
|
‡2
LC|no2014006318
|
|
996
|
|
|
‡2
RERO|A012339288
|
|
996
|
|
|
‡2
N6I|vtls000077271
|
|
996
|
|
|
‡2
CAOONL|ncf11444653
|
|
996
|
|
|
‡2
ISNI|0000000434926442
|
|
996
|
|
|
‡2
ISNI|0000000399059987
|
|
996
|
|
|
‡2
LC|n 82134700
|
|
996
|
|
|
‡2
NII|DA19578185
|
|
996
|
|
|
‡2
NTA|071337091
|
|
996
|
|
|
‡2
RERO|A023895397
|
|
996
|
|
|
‡2
DNB|1011622378
|
|
996
|
|
|
‡2
SUDOC|085967289
|
|
996
|
|
|
‡2
RERO|A012373727
|
|
996
|
|
|
‡2
DNB|133168875
|
|
996
|
|
|
‡2
ISNI|0000000110326731
|
|
996
|
|
|
‡2
LC|n 80149497
|
|
996
|
|
|
‡2
DNB|1345815662
|
|
996
|
|
|
‡2
ISNI|0000000050387494
|
|
996
|
|
|
‡2
SUDOC|158550161
|
|
996
|
|
|
‡2
ISNI|0000000046725200
|
|
996
|
|
|
‡2
DNB|1019149507
|
|
996
|
|
|
‡2
NTA|074264591
|
|
996
|
|
|
‡2
LC|nb2013012231
|
|
996
|
|
|
‡2
J9U|987007271769605171
|
|
996
|
|
|
‡2
ISNI|0000000081093480
|
|
996
|
|
|
‡2
J9U|987007440005905171
|
|
996
|
|
|
‡2
SUDOC|280958498
|
|
996
|
|
|
‡2
LC|n 2009000213
|
|
996
|
|
|
‡2
LC|n 84109803
|
|
996
|
|
|
‡2
CAOONL|ncf10529329
|
|
996
|
|
|
‡2
LC|nb2015022151
|
|
996
|
|
|
‡2
ISNI|0000000496475149
|
|
996
|
|
|
‡2
BIBSYS|90779740
|
|
996
|
|
|
‡2
ISNI|0000000074140795
|
|
996
|
|
|
‡2
B2Q|0000049144
|
|
996
|
|
|
‡2
CAOONL|ncf11630335
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
|
998
|
|
|
‡a
Price, David
‡q
(David B.)
‡2
LC|nb2011018587
‡3
exact title: (1.00, 'pragmaticsingleblindrandomisedcontrolledtrialandeconomicevaluationoftheuseofleukotrienereceptorantagonistsinprimarycareatsteps2and3ofthenationalasthmaguidelineselevatestudy', 'pragmaticsingleblindrandomisedcontrolledtrialandeconomicevaluationoftheuseofleukotrienereceptorantagonistsinprimarycareatsteps2and3ofthenationalasthmaguidelineselevatestudy')
‡3
suggested
|
|
998
|
|
|
‡a
Price, David
‡2
ISNI|0000000355447064
‡3
exact name
|
|
998
|
|
|
‡a
David Price
‡2
ISNI|0000000355447064
‡3
exact name
|
|
998
|
|
|
‡a
Price, David
‡2
ISNI|0000000355447064
‡3
exact name
|
|
998
|
|
|
‡a
Price, David
‡q
(David B.)
‡2
BNC|981061111746606706
‡3
viafid
‡3
exact title: (1.00, 'effectofmontelukastonlungfunctioninasthmapatientswithallergicrhinitisanalysisfromthecompacttrial', 'effectofmontelukastonlungfunctioninasthmapatientswithallergicrhinitisanalysisfromthecompacttrial')
|
